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Preamble
This document has been developed as an Expert Consensus
Document (ECD) by the American College of Cardiology
Foundation (ACCF), American Association for Thoracic
Surgery (AATS), Society for Cardiovascular Angiography
and Interventions, and the Society of Thoracic Surgeons in
collaboration with the American Heart Association (AHA),
American Society of Echocardiography, European Associ-
ation for Cardio-Thoracic Surgery, Heart Failure Society of
America, Society of Cardiovascular Computed Tomogra-
phy, Society of Cardiac Magnetic Resonance, Society of
Cardiovascular Anesthesiologists, and Mended Hearts.
ECDs are intended to inform practitioners, payers, and
other interested parties of the opinion of ACCF and
document cosponsors concerning evolving areas of clinical
practice and/or technologies that may be widely available or
may be new to the practice community. Topics chosen for
coverage by ECDs are so designed because the evidence
base, the experience with technology, and/or clinical prac-
tice are not considered sufficiently well developed to be
evaluated by the formal ACCF/AHA Practice Guidelines
process. Often the topic is the subject of considerable
ongoing investigation. Thus, the reader should view the
ECD as the best attempt of the ACCF and document
cosponsors to inform and guide clinical practice in areas
where rigorous evidence may not yet be available or evidence
to date is not widely applied to clinical practice. When
easible, ECDs include indications or contraindications. Some
opics covered by ECDs will be addressed subsequently by the
CCF/AHA Practice Guidelines Committee.
To avoid actual, potential, or perceived conflicts of
nterest that may arise as a result of industry relationships or
ersonal interests among the writing committee, all mem-
ers of the writing committee, as well as peer reviewers of
he document, are asked to disclose all current healthcare-
elated relationships, including those existing 12 months
efore initiation of the writing effort. The ACCF Task Force
n Clinical Expert Consensus Documents (TF CECD) re-
iews these disclosures to determine what companies make
roducts (on market or in development) that pertain to the
ocument under development. Based on this information, a
riting committee is formed to include a majority of
embers with no relevant relationships with industry or
ther entity (RWI), led by a chair with no relevant RWI.
uthors with relevant RWI are not permitted to draft or
ote on text or recommendations pertaining to their RWI.
WI is reviewed on all conference calls and updated as
hanges occur. Author and peer reviewer RWI pertinent to
his document are disclosed in Appendices 1 and 2, respec-
ively. Additionally, to ensure complete transparency, authors’
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March 27, 2012:1200–54 Transcatheter Aortic Valve Replacementcomprehensive healthcare-related disclosure information—
including RWI not pertinent to this document—is available
online (see Online Appendix 3). Disclosure information for
the ACCF TF CECD is also available online at
www.cardiosource.org/ACC/About-ACC/Leadership/
Guidelines-and-Documents-Task-Forces.aspx, as well as
the ACCF disclosure policy for document development at
www.cardiosource.org/Science-And-Quality/Practice-
Guidelines-and-Quality-Standards/Relationships-With-
Industry-Policy.aspx.
The work of the writing committee was supported
exclusively by the ACCF without commercial support.
Writing committee members volunteered their time to this
effort. Conference calls of the writing committee were
confidential and attended only by committee members.
Robert A. Harrington, MD, FACC
Chair, ACCFTask Force onClinical Expert ConsensusDocuments
1. Introduction
1.1. Document Development Process
1.1.1. Writing Committee Organization
The Writing Committee consisted of a broad range of
members representing 12 societies and the following
areas of expertise: cardiothoracic surgery, interventional
cardiology, general cardiology, geriatric cardiology, echo-
cardiography, cardiac anesthesiology, cardiac computed
tomography (CT), cardiac magnetic resonance (CMR),
cardiac nursing, heart failure, neurology, valvular heart disease,
structural heart disease, and the consumer perspective. Geo-
graphic distribution of members crossed most U.S. time zones
and included international representation. Members with ex-
pertise using this new and emerging technology and those with
expertise in their content area, but not in the procedure
discussed herein, served on the committee to provide appro-
priate balance of perspectives.
This writing committee met the College’s disclosure
requirements for relationships with industry as described in
the Preamble. Important to note, if an author works in an
institution that serves as a TAVR trial site but has no direct
relationship with the trial sponsor or other relevant com-
pany (that produces [competing] products or services dis-
cussed in this document) or institutional relationship as
defined by the ACCF Disclosure Policy for Document
Development, the trial site information was not deemed
relevant to this writing effort and is not included in the table
of relevant author disclosures (Appendix 1). For example, if
an author works in an institution where TAVR is per-
formed, but he/she: 1) does not personally perform the
procedure; or 2) performs the procedure but has no direct
relationship to the trial (e.g., principal investigator, investi-
gator, steering committee member, consultant) and does not
oversee funds related to the trial, then the relationship is not
included in the table of relevant disclosures. In thesesituations, these relationships do not even need to be
disclosed. However, in the spirit of full disclosure, this
information is recorded in the online disclosure table con-
taining all author healthcare relationships.
1.1.2. Document Development and Approval
The Writing Committee convened by conference call and
e-mail to finalize the document outline, develop the initial
draft, revise the draft per committee feedback, and ulti-
mately sign off on the document for external peer review. All
participating organizations participated in peer review, re-
sulting in 48 reviewers representing 1,087 comments. Com-
ments were reviewed and addressed by the writing committee.
A member of the ACCF TF CECD served as lead reviewer to
ensure that all comments were addressed adequately. Both the
Writing Committee and TF CECD approved the final doc-
ument to be sent for board review. The ACCF Board of
Trustees, AATS Council, SCAI Board of Directors, and STS
Board of Directors reviewed the document, including all peer
review comments and Writing Committee responses, and
approved the document in January 2012. The AHA, ASE,
EACTS, HFSA, Mended Hearts, SCA, SCCT, and SCMR
endorsed the document in January 2012. This document is
considered current until the TF CECD revises or withdraws it
from publication.
1.2. Purpose of This Document
Transcatheter aortic valve replacement (TAVR) offers new
and potentially transformational technology for patients
with severe aortic valvular stenosis who are either extremely
high-risk candidates or inoperable for surgical aortic valve
replacement (AVR) or who are inoperable by virtue of
associated comorbidities. In the future, this technology may
be utilized in lower risk surgical candidates. An estimated
40,000 patients have received TAVR worldwide. Multiple
single and multicenter registries, and a single randomized
trial, have documented favorable outcomes using a wide
spectrum of endpoints, including survival, symptom status,
quality of life, and need for repeat hospitalization. The
implementation of TAVR into the flow of patient care is
complex, involving consideration of several key factors such
as clinical site selection, operator and team training and
experience, patient selection and evaluation, procedural
performance and complication management, and postpro-
cedural care. Collaborative stakeholder involvement is re-
quired in the management of this high-risk patient popu-
lation with extensive coexistent medical conditions. A
previously published document by ACCF and STS identi-
fied a high-level series of issues to be addressed regarding
this technology (1). This current collaborative expert con-
sensus document, which involves 12 professional societies,
addresses these issues in greater detail with the intent to
examine the current state of the evidence, facilitate the
integration of this technology into the armamentarium of
therapeutic options for patients with aortic valvular stenosis,
and to enable responsible adoption and diffusion of this
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lished data; it must be remembered that there is only 1
single completed randomized trial, although others are in
progress or planned; much of the data in this expert
consensus document is based upon information from studies
and registries, both surgical and TAVR, which are fre-
quently retrospective and include self-reported clinical
events rather than adjudicated events.
2. Background and Historical Aspects
The most common cause of valvular aortic stenosis (AS) in
adults is calcification of a normal trileaflet or congenital
bicuspid valve (2–4). Calcific AS is characterized by lipid
accumulation, inflammation, fibrosis, and calcification (5,6)
and is common in the United States. It typically presents in
older individuals (i.e., 75 years) in contrast to bicuspid
AS, which presents a decade or more earlier. Rheumatic AS,
uncommon in the Western world, occurs due to fusion of
the commissures with scarring and calcification of the cusps,
and retraction of the leaflets resulting in the valve being
both regurgitant and stenotic.
2.1. Pathophysiology and Clinical Course
In adults with valvular AS, the obstruction develops grad-
ually, typically over many years during which the left
ventricle (LV) adapts to the systolic pressure overload with
progressive concentric hypertrophy that results in diastolic
dysfunction (4,7,8), reduced coronary reserve (9,10), myo-
cardial ischemia (11), and eventually, depressed contractility
resulting in LV systolic dysfunction (12–14). Ultimately, in
some patients, heart failure or sudden death occurs. Typi-
cally, patients with AS are free from cardiovascular symp-
toms (i.e., angina, syncope, and heart failure) until late in
the course of the disease. However, once symptoms mani-
fest, the prognosis is poor, with the interval from the onset
of symptoms to the time of death being approximately 2
years in patients with heart failure, 3 years in those with
syncope, and 5 years in those with angina (15). Gardin et al.
reported that among symptomatic patients with moderate-
to-severe AS treated medically, mortality rates after the
onset of symptoms were approximately 25% at 1 year and
50% at 2 years (16), with approximately 50% of deaths being
sudden. In the elderly high-risk patients in the PARTNER
(Placement of Aortic Transcatheter Valve) trial who were
treated medically (Cohort B), the survival at 1 year was only
50% (15).
The natural history of AS has changed since the publi-
cation of the seminal paper by Morrow and colleagues in
1968 (17). The original data were derived largely from
patients with rheumatic AS or AS due to a bicuspid aortic
valve, with an average age of death of 63 years. On the
contrary, patients being considered for TAVR on a trileaflet
valve present much later in life, typically in their late 70s or
older, and have dominantly fibrocalcific AS. Although nowoccurring later in life, the onset of symptoms still heralds a
rapid decline with medical therapy alone (15).
2.2. Diagnosis
2.2.1. Echocardiography Versus Catheterization
Assessment of the severity of stenosis does not differ in
TAVR patients compared with the general AS population,
and decisions should therefore be based upon established
guidelines (18). Although invasive cardiac catheterization
has historically been the standard for quantification of
AS, this function has been largely replaced by echocar-
diography (19).
Echocardiographic diagnosis is made by the observation
of a calcified valve with restricted leaflet opening by two-
dimensional (2D) echocardiography with quantification of
the peak and mean AV gradient made by applying the
simplified Bernoulli equation (p  4v2) to the maximal
elocity recorded through the aortic valve by continuous-
ave Doppler. Multiple imaging windows (apical
-chamber and long-axis, right parasternal, suprasternal
otch, and subcostal views) should be obtained to assure
cquisition of the maximal velocity and to avoid angle-
elated errors. Although aortic valve area (AVA) can be
easured by planimetry, it is more accurately assessed by
pplication of the continuity equation, using pulsed-wave
oppler in the left ventricular outflow tract (LVOT) and
ontinuous-wave Doppler across the valve. Severe stenosis is
efined in the guidelines as a peak velocity 4.0 m/s
corresponding to a peak gradient of 64 mm Hg), a mean
radient 40 mm Hg, OR valve area 1.0 cm2 when LV
systolic function is normal. To account for patient size, the
valve area is often indexed to body surface area, with 0.6
cm2/m2 considered to be the threshold for severe AS. An
mportant exception is when the gradient suggests less
evere stenosis than the valve area, most commonly due to
ow stroke volume, either in dilated ventricles with low
jection fraction (EF) or small ventricles with normal EF. In
his setting, a dobutamine stress study (maximum stress
ose 20 mcg/kg/min), may be helpful. If the maximum jet
elocity rises over 4 m/s with the dobutamine-induced
ncrease in stroke volume whereas the AVA remains less
han 1.0 cm2, then the valve is truly severely stenotic. On
the other hand, if stroke volume increases with little rise in
gradient (causing valve area to increase substantially), then
the AS is only mild to moderate in severity, and the LV
dysfunction is due to causes other than AS (20–22).
Occasionally, the AVA appears larger than the elevated
gradient would suggest, usually due to elevated stroke
volume from aortic regurgitation (AR), anemia, fever, or
hyperthyroidism. Sometimes, though, it reflects a technical
error in applying the continuity equation, when the blood
accelerates within the LVOT due to an upper septal bulge,
which may result in an overestimation of valve area. To
avoid this, one can try to measure the LVOT area at the
point of maximal velocity, though the geometry is often
5
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LVOT area difficult. Alternatively, one can use the LV
stroke volume (from 2D or three-dimensional [3D] mea-
surements of the LV, ideally with contrast infusion) or right
ventricular (RV) stroke volume (from RV outflow tract) as
the input into the continuity equation. Dividing this stroke
volume by the time velocity integral of the AV continuous-
wave Doppler will also yield the AVA, independent of any
distortion in the LVOT.
Despite the convenience and wide-spread applicability of
transthoracic echocardiography (TTE), there are occasions
when invasive measurements are needed, such as in patients
with a discrepancy between clinical and echocardiographic
assessments. In such cases, catheterization should generally
be performed with dual catheters, 1 placed in the LV, the
other in the proximal aorta to obtain simultaneous pressure
measurements and obtain the most accurate assessment of
the gradient. Infusion of dobutamine may allow assessment
of low-output, low-gradient AS in the catheterization
laboratory (23). Other adjunctive testing used in quantifying
AS includes transesophageal echocardiography (TEE) (24),
CT scanning (dynamic or gated during systole) (25), and
CMR (26).
2.2.2. Stress Testing
The presence or absence of symptoms should guide the
management of AS patients, yet in many cases, this impor-
tant clinical benchmark is difficult to establish, owing to the
subjective nature of the symptoms and comorbid conditions
such as chronic lung disease in this patient population. In
general, stress testing is contraindicated when symptoms are
present because of the potential for complications in these
patients. However, in patients with equivocal symptoms,
stress testing, and in particular stress echocardiography, can
be very helpful (27). Simple determination of functional
capacity may help show limitations of which a patient may
be unaware. Isolated echocardiographic (ECG) changes
during the stress test without symptoms or change in blood
pressure should not be interpreted as a positive indicator of
severe AS. Other potential markers for AS severity include
signs of LV dysfunction on exercise echo or a rise in left
atrial or right ventricular pressure (28,29).
2.3. Special Considerations
2.3.1. Symptom Status
With severe, symptomatic, calcific AS, AVR is the only
effective treatment that improves symptoms and prolongs
survival (30,31). These results are partly dependent on LV
function. In the setting of LV dysfunction caused by
afterload mismatch, survival is still improved, although
improvement in LV function and resolution of symptoms
might be incomplete after AVR. Age itself is a risk factor for
adverse outcome, but it is not a contraindication to AVR
even in the very elderly (32,33). r2.3.2. Associated Coronary Artery Disease
In patients with moderate AS, who are undergoing coronary
artery bypass graft surgery (CABG), AVR should be per-
formed at the time of revascularization irrespective of
symptoms related to moderate AS (34,35). There are no
data to support performing AVR for mild AS at the time of
CABG. Patients undergoing surgical AVR with significant
stenoses (50% to 70% stenosis) in major coronary arteries
should be treated with concomitant CABG. Options in
patients with combined AS and CAD continue to grow
with the use of hybrid procedures where PCI is followed by
valve surgery. It is possible that such a strategy could be
performed in the setting of TAVR (36,37).
2.3.3. Associated Lesions—AR, MR, Pulmonary
Hypertension, TR
Patients with severe AS often have additional associated
significant valvular heart disease. Treatment of these lesions
in patients undergoing AVR should be undertaken using
standard criteria. However, treatment of associated valvular
lesions may increase the risk of AVR (38). A special
circumstance is that of pulmonary hypertension (PH) either
primary or secondary (reactive or related to increased LV
end-diastolic pressure). Both conditions may increase the
risk of AVR and must be taken into consideration in the
risk/benefit ratio.
PH can be present in patients with severe AS, either from
the transmission of increased LV diastolic and/or left atrial
pressures, associated mitral regurgitation (MR), or from a
secondary increase in pulmonary vascular tone. The preva-
lence of PH in patients with AS is undefined, varying widely
on the definition used and the population studied (39,40).
Clinically, PH associated with critical AS portends a poor
prognosis and is associated with an increased risk of sudden
cardiac death (41). Consistent with the surgical valve
implant experience, PH after TAVR is a predictive factor
for both early (30-day) and late (1-year) mortality, similar in
risk to major access site complications and renal insuffi-
ciency (39,42– 46). The presence of PH makes patients
more susceptible to any hemodynamic and electrical
instability related to the procedure and may increase the
risk of postprocedural complications. In addition, PH
may result in right heart failure and severe tricuspid
regurgitation (TR), both of which complicate manage-
ment and increase risks.
In the setting of severe AS and PH several treatment
strategies have been used (47). Persistently elevated left-
sided cardiac filling pressures increase the risk of pulmonary
edema when challenged with a pulmonary vasodilator.
Pulmonary vasodilators, such as nitric oxide, prostacylin,
and sildenafil, have been administered during and following
cardiac surgery with improved hemodynamic effects (48–
0). However, their overall clinical utility in improving late
urvival in the surgical population and their role in TAVR
emains unclear. Further investigation is needed to deter-
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ment of patients with AS and PH undergoing TAVR.
2.3.4. Low Gradient–Low EF
As mentioned, the combination of overt congestive heart
failure and low aortic valve gradient is relatively common.
This may be a consequence of excessive afterload (despite
left ventricular hypertrophy [LVH]) or reduced contractile
function (51) likely due to increased myocardial fibrosis (52).
When there is overt heart failure due to low forward flow
and a low transvalvular gradient (mean gradient 30 mm
g), both mechanisms may be present. Because of reduced
ontractility in the low-flow/low-gradient AS patient, prog-
osis with surgical AVR is adversely affected with operative
ortality as high as 20%. However the 5-year survival is still
eported to be better in patients treated surgically (53,54).
hen the primary reason for poor LV performance is
xcessive afterload, the prognosis following surgical AVR is
sually good (14). In general, patients with low gradient,
ow EF who have the best prognosis are those with inotropic
eserve (shown by an increase in stroke volume with
obutamine infusion), who have limited coronary disease
nd a mean gradient that although low, still exceeds 20 mm
g (53).
.3.5. Basal Septal Hypertrophy—Outflow Tract
radients
lthough infrequent, proximal septal bulging with LVOT
bstruction may present unique issues in the presence of AS.
hile this can be readily addressed during AVR via
yomectomy, such an approach would not be possible with
AVR. Thus, careful preprocedural echocardiographic
creening is recommended to specifically avoid this scenario
n patients being considered for TAVR.
3. Current Treatment Options
3.1. Surgical AVR
AVR is the only effective treatment considered a Class I
recommendation by ACCF/AHA and ESC guidelines in
adults with severe symptomatic AS (28,29). Not only does
it offer symptomatic relief, the operation improves long-
term survival. Since 1960, when AVR was first introduced,
advancement in prosthetic technology including improved
hemodynamics, durability and thromboresistance, and tech-
niques in cardiac surgery such as cardioplegia, management
of the small aortic root, resection of associated subvalvular
disease, and replacement of associated aortic aneurysm have
resulted in improvements in both operative and long-term
results.
3.1.1. Valve Type
Current AVR options include mechanical, bioprosthetic,
and in specific situations homograft and autograft tech-
niques. Each has their advantages and drawbacks, but the wtrend in some centers in the recent era has been toward
tissue valve replacement in a majority of patients because of
improved durability and the lack of requirement for antico-
agulation therapy.
3.1.1.1. MECHANICAL VALVES
Mechanical valves are now extremely durable, have excellent
hemodynamics, and are minimally thrombogenic with ad-
equate anticoagulation. Current anticoagulation is mostly
based on Vitamin K antagonists. Newer agents such as oral
direct thrombin inhibitors and factor Xa inhibitors have
been studied in other patient populations, mainly atrial
fibrillation, and have been found to be associated with
decreased bleeding risk and minimum drug or food inter-
action (55). They have not been well studied in patients
with AVR. With warfarin there is a risk of serious throm-
boembolism of approximately 0.5% a year and a similar risk
of major hemorrhage annually (56). Mechanical valves are
typically preferred in younger patients given their reliable
long-term durability.
3.1.1.2. BIOPROSTHETIC VALVES
Compared with mechanical valves, bioprosthetic valves do
not require anticoagulation with warfarin, and thus have a
lower risk of bleeding. However, long-term durability varies
substantially with age for these valves. Structural valve
degeneration leading to symptoms or reoperation, com-
monly associated with calcification of the biologic leaflets,
occurs at an average of 10 to 12 years in younger patients
and 15 to 18 years in older patients. Actuarial freedom from
reoperation following implant of a modern bioprosthetic
valves is approximately 95% at 5 years, 90% at 10 years, but
drops to 70% at 15 years (57). Thus, bioprosthetic valves are
generally preferred in older patients who are unlikely to
tolerate bleeding risk associated with anticoagulation treat-
ment and in whom a 15-year durability is reasonable. In
patients with bioprosthetic valves, if prosthetic dysfunction
occurs, TAVR may play an important role in solving the
clinical issues in the future.
3.1.2. Procedural Hazards
Current data from the Society of Thoracic Surgeons (STS)
registry documents a mortality that is under 3% for all
patients undergoing AVR. As with any procedure, operative
mortality is strongly correlated with the severity of the
disease and comorbidity of patients. The operative risks can
be estimated with online risk calculators from the STS
(http://209.220.160.181/STSWebRiskCalc261/) and the
uropean System for Cardiac Operative Risk Evaluation
www.euroscore.org) (58,59). In selected patients with min-
mal comorbidity, mortality and major morbidity are under
% each in many centers. In general, perioperative stroke
ates are 1.5% (with major life-debilitating stroke being
omewhat less) and other major complications are relatively
are. Renal failure, pulmonary failure, and gastrointestinal
omplications are not common. As older, more frail patients
ith extensive comorbidities undergo AVR, the risk of
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increases significantly (60,61). In addition to comorbidity,
preoperative functional performance is also a maker of post-
operative morbidity/mortality.
A recent study reviewed the results of high-risk surgical
AVR in 4 centers with significant experience. The patients
were a mean age of 76 and the mean STS predicted risk of
mortality was 16.3%. Complications included stroke in
4.4%, new permanent pacemaker in 5%, multisystem organ
failure in 6.9%, pneumonia in 7.5%, and dialysis in 8.2%.
Postoperative length of stay was 12.6 days and in-hospital
mortality was 16.4%. One-, 3- and 5-year survival was
70.9%, 56.8%, and 47.4%. This study was performed
between 2002 and 2007 in 4 centers before participation in
the PARTNER Trial commenced and therefore serves as a
reasonable baseline for comparing the results of TAVR (62).
3.1.3. Patient Selection
Patient selection for AVR for AS is well outlined by
ACCF/AHA and ESC guidelines (29,63). Problems arise
when the clinicians and patients note significant symptoms
and significant structural disease that are complicated by the
presence of significant comorbidity. Although current STS
risk score and EuroSCORE give information concerning
short-term operative risks and benefits, they are not able to
predict symptom resolution, quality-of-life improvement, or
return to independent living.
3.1.3.1. USE OF STS AND EUROSCORE MODELS IN PATIENT SELECTION FOR
CONVENTIONAL AVR
Although a number of risk algorithms for cardiac surgery
have been developed, the STS and logistic EuroSCORE are
the most commonly used. Although both are accurate in
low-risk patients, accuracy is less in higher-risk subsets.
These 2 scores include different covariates. The logistic
EuroSCORE is based on 12 covariates derived from 14,799
patients undergoing all types of cardiac operations (mostly
coronary bypass) in 8 European countries in 1995. On the
other hand, the STS risk predictor is based on 24 covariates
derived from 67,292 patients undergoing isolated AVR only
in the United States over a relatively more contemporary
period between 2002 and 2006. The STS model is the
standard most commonly used in the United States.
3.1.3.2. PATIENT RISK OF AVR
Information from the STS National Database shows that
the operative mortality for isolated AVR has declined from
3.4% in 2002 to 2.6% today (http://www.sts.org/sites/
default/files/documents/20112ndHarvestExecutiveSummary.
pdf). The most important preoperative patient risk factors
are the need for emergency surgery, the presence of
endocarditis, and a history of previous cardiac surgery.
The present models do not include some risk factors that
may be particularly important in the prediction of out-
comes for very high-risk populations including frailty,
PH, porcelain aorta, and the presence of hepatic dysfunc-tion, although all have been added to a recent upgraded
version (64,65).
It should be emphasized that risk models serve as 1 aspect
of patient selection, but need to be considered in concert
with clinical judgment and the other methods of risk
assessment. In the final analysis, patient risk and benefit is
determined, not by statistical models, but by the experience,
knowledge, and expertise of the physicians charged with
rendering care.
3.1.3.2.1. SPECIFIC SURGICAL RISKS
3.1.3.2.1.1. Stroke. Although ischemic stroke can result from
many causes after AVR, a major concern is the role of
thromboembolism. The risks of thromboembolism are usu-
ally greater in the first few days and months after biopros-
thetic AVR implantation before the sewing ring of the
prosthesis is endothelialized (66); risks after mechanical
AVR continue. The risk of stroke within 30 days among
67,292 cases of AVR in the STS Registry was 1.5%; this
data set was used to develop a model for predicting 30-day
stroke risk (61). Within the STS database among 108,687
AVR operations between 1996 through 2006, the risk of
in-hospital permanent stroke decreased 21% from 1.7% to
1.3% (67). It is important to note, however, that indepen-
dent neurological assessment was not done in these
patients, so the actual stroke incidence in these patients
may be underestimated. Overall, embolic stroke risks are
greater with mechanical valves, which require long-term
oral anticoagulation, than with bioprosthetic valves,
which have a 0.7% per year risk of thromboembolism in
patients with normal sinus rhythm without warfarin
anticoagulation (68).
Of note, many AVR patients are older, with other
comorbid cardiac conditions that increase stroke risk, in-
cluding atrial fibrillation, cardiomyopathy, and carotid ste-
nosis or aortic arch atheroma (69). However, even carefully
selected octogenarians can safely undergo AVR with a 2%
incidence of stroke (32,70).
Because of the risk of stroke, the 2006 ACC/AHA
guidelines for the management of patients with valvular
heart disease include a variety of recommendations regard-
ing the use of antithrombotic therapy to reduce thrombo-
embolism risk after AVR (63). The choice of antithrom-
botic agents include warfarin with target international
normalized ratios (INRs) typically in the range from 2.0 to
4.0 depending on the specific prosthesis, aspirin 75 mg to
325 mg per day, and clopidogrel 75 mg per day, as well as
combinations. Recommendations depend upon the type of
valve, timing after surgery, presence or absence of risk
factors such as atrial fibrillation, and ability of the patient to
take warfarin or aspirin (63).
Given the greater risk of thromboembolism, particularly
stroke, which usually occurs within the first 72 hours
post-procedure, many centers start heparin (target aPTT
55 s to 70 s) as soon as the risk of surgical postoperative
bleeding is acceptable, which is usually within 48 hours of
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apy reaches a therapeutic INR usually above 2.0 (63).
3.1.3.2.1.2. Other Complications. Aside from other surgical
complications of renal, hepatic, neurological, and pulmo-
nary disease compromise, a major risk of conventional AVR
is sternal wound infection. In most centers, this risk is under
1% for deep infection, but the risk of any type of infection
is still present and particularly increased in patients with
diabetes, obesity, smoking, immunosuppressive therapy, and
prior radiation therapy. With the advent of negative pres-
sure wound therapy and continued advances in surgical
technique, these risks are now rarely fatal, but remain
morbid. Blood requirement after valve replacement can lead
to hepatitis C, human immunodeficiency virus, or other
viral infection. These transfusion-acquired infections are
now extremely rare due to transfusion guidelines and sys-
tems precautions.
3.1.3.3. PROHIBITIVE RISK, EXTREME RISK, INOPERABILITY
Despite substantial contemporary experience with successful
AVR in elderly patients, multiple series have documented
that 30% to 40% of patients with severe AS do not undergo
surgery owing to advanced age, LV dysfunction, multiple
coexisting conditions, and patient preference or physician
recommendation (71–76).
The definitions used to describe patient populations
considered for TAVR vary; for example, prohibitive risk
would describe a patient in whom the procedure could be
performed from a technical standpoint but would be asso-
ciated with prohibitively high morbidity and mortality (77).
Inoperability might identify a patient group in whom
technical success would not be possible; for example, no
vascular access. Different trials have used these terms for
patient enrollment; for example, the CoreValve Trial iden-
tifies extreme risk, whereas the PARTNER (Placement of
AoRtic TraNscathetER Valve) Trial used the term inoper-
ble. For this document, we prefer the term prohibitive risk.
his includes some patients in whom surgery might be
eemed unsuitable based on the physician’s assessment of
he patient’s risk for surgery; whereas in others, the surgeon
ay decide that the operation cannot be performed success-
ully because of technical considerations. Assessment of
noperability is also driven by surgeon and institutional
xperience and thus varies. The incidence of patients un-
ergoing AVR with an STS predicted risk of mortality
5% is low but vary significantly amongst institutions and
ay be related to volume and referral patterns. Experience
ith such patients is pivotal for TAVR teams. Referral to
uch team and another opinion/consultation is crucial be-
ore deeming a patient inoperable. Whereas practice guide-
ines have been developed to assist physicians and surgeons
n determining appropriate use of treatment options
29,63), there are, however, no specific recommendations
or defining inoperability. Current ACCF/AHA guidelines
cknowledge that special considerations are required for the
anagement of advanced elderly patients with AS, sinceage-related and comorbid conditions commonly exist in
patients in their 80s and 90s even though AVR is technically
feasible even in this group (67,78).
In the absence of literature evidence and guidelines
recommendations, the determination of inoperability in any
given patient depends on the judgment of the medical team.
It is generally agreed that patients with limited life expec-
tancy due to concurrent conditions such as malignancy,
dementia, primary liver disease, chronic obstructive pulmo-
nary disease (COPD), among others, are not appropriate for
AVR. Frailty and related conditions of debility and decon-
ditioning are known to result in inability to recover from
major heart surgery such as AVR, despite operative survival
and hospital discharge (65). These conditions can poten-
tially contribute to increased surgical mortality and morbid-
ity in the elderly (79).
Inoperability from the surgeon’s judgment may result
from technical considerations that preclude safe perfor-
mance of AVR, such as prior mediastinal irradiation,
porcelain aorta or severe periannular calcification, severe
aortic atheromatous disease, prior cardiac operations,
among others including the internal mammary artery cross-
ing the midline. Although infrequent, aortic valve bypass
with a LV apex-to-descending aortic conduit has been used
in some patients with severe AS judged to be inoperable via
a mediastinal approach and cardiopulmonary bypass (80).
In summary, a substantial percentage of patients with AS
are judged to be inoperable for surgery based primarily on
the physician’s or surgeon’s determination of operative risk
and survivability. Although some patients may be found to
be inoperable for technical and surgical reasons, most
inoperable patients are felt to be too ill from associated
comorbid conditions.
3.2. Alternatives to AVR
3.2.1. Medical Therapy
There are no proven medical treatments to prevent or delay
the disease process in the aortic valve leaflets. However,
evaluation and modification of cardiac risk factors is impor-
tant in patients with aortic valve disease to prevent concur-
rent coronary artery disease (CAD). The association of AS
with risk factors similar to those associated with atheroscle-
rosis (5,6) had suggested that intervention may be possible
to slow or prevent disease progression in the valve leaflet
(81,82), but prospective, randomized, placebo-controlled
trials failed to demonstrate a benefit of statins in reducing
the progression of aortic valve stenosis.
Longer-term palliative medical management of symp-
tomatic AS may be appropriate for patients who are either
not candidates for aortic valve surgery due to comorbidities
or in patients who refuse AVR. The overall goal of medical
therapy is to treat coexisting cardiovascular conditions, and
treat superimposed diseases that often exacerbate the disease
process. Patients should be educated about the effects of
sodium intake, change in weight, and other factors that may
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judicious and include treating concurrent cardiovascular
conditions such as correction of anemia and fever, and
preventative measures such as pneumococcal or influenza
vaccination. Given the severe hypertrophy, optimizing he-
modynamics by maintaining sinus rhythm may help with
symptom stabilization.
Even with optimal care, adults with severe symptomatic
inoperable AS will have exacerbations of symptoms and
frequent hospitalizations. Palliative care should include
end-of-life discussions and counseling as appropriate.
Counseling is also indicated regarding true risk of AVR, and
the importance of accurate risk prediction cannot be over-
emphasized. Many patients may refuse surgery based on
misunderstood operative risk.
3.2.2. Balloon Aortic Valvuloplasty
First reported in 1986 (83), balloon aortic valvuloplasty was
considered to be a less invasive and safe alternative to AVR,
particularly in high surgical risk patients with multiple
medical comorbidities. Although balloon aortic valvulo-
plasty results in immediate hemodynamic improvement
with a significant decrease in transvalvular gradients result-
ing in larger valve area, it does not result in sustained clinical
improvement because of high recurrence rates; restenosis or
recoil of the aortic valve usually occurs within 6 months.
Patients treated with balloon aortic valvuloplasty alone have
shown poor prognosis, with survival rates of 50% at 1 year,
35% at 2 years, and 20% at 3 years (15,84–86). In addition,
serious complications due to balloon aortic valvuloplasty
occur in 15% to 25% of patients (84,87,88). Balloon aortic
valvuloplasty, therefore, should not be used as a substitute
for AVR in patients who are candidates for surgical AVR.
Even as a palliative treatment, balloon aortic valvuloplasty
data suggest that there is much uncertainty regarding
improved longevity or quality of life after the procedure with
a mean duration of symptom improvement of only 1 year
(63,89). There has been no significant difference in long-
term survival demonstrated between patients undergoing
balloon aortic valvuloplasty and those undergoing medical
therapy alone (86). Although balloon aortic valvuloplasty as
a stand-alone treatment is not recommended (63,87,88), it
may still be used in contemporary practice as a bridge to
subsequent AVR (both Class IIb, Level of Evidence C
recommendation) (28,84,90). In the current era of TAVR,
there has been increased interest in balloon aortic valvulo-
plasty. In this setting, balloon aortic valvuloplasty may be used
to assess whether there is initial clinical improvement, in which
case, then the patient may be a candidate for TAVR.
4. Transcatheter Aortic Valve Replacement
4.1. Background and History
Given the increased mortality and morbidity of AVR
surgery for high-risk patients and the poor long-term resultsof balloon aortic valvuloplasty, there has been interest in the
development of a percutaneously delivered aortic heart valve
(91). As early as 1992, investigators evaluated stent-based
porcine bioprostheses delivered to various aortic sites in
animal models (92). This early work culminated in 2000
with implantation of a percutaneous heart valve in a 12-
year-old patient with a failing right ventricular to pulmonary
arterial conduit that had been placed 8 years previously for
the treatment of pulmonary atresia and ventricular septal
defect. This initial seminal experience was followed in 2002
by the first human TAVR using the antegrade approach to
implant a balloon expandable equine pericardial leaflet stent
valve (93). Since that early experience, there have been
multiple iterations and a number of new designs.
4.2. Device Description
At the present time, the most data available for TAVR are
based upon 2 specific devices—the Sapien valve (Figure 1)
Edwards Life Sciences, Inc., Irvine, CA) and the CoreValve
(Figure 2) (Medtronic, Inc., Minneapolis, MN). The most
recent iteration of the former is a trileaflet bovine pericardial
valve mounted with a tubular slotted balloon-expandable
stent composed of a cobalt chromium alloy. The Sapien valve
is available in 23-mm and 26-mm sizes in the United States
and 23-mm, 26-mm, and 29-mm sizes in Europe. The initial
devices required a 22- or 24-French sheath for delivery of the
prosthesis. Recent iterations (NovaFlex) have decreased this to
18-French. The first and second generations of this device have
been tested in randomized controlled trials for both transfemo-
ral and transapical implantation.
The second device (CoreValve) is comprised of 3 porcine
pericardial tissue leaflets mounted in a self-expanding ni-
tinol frame. It is available in 3 sizes—26 mm, 29 mm, and
31 mm. This valve has also continued to iterate, with the
initial devices being 25-French, but now 18-French delivery
Figure 1. Sapien ValveSource: Edwards Lifesciences.
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Transcatheter Aortic Valve Replacement March 27, 2012:1200–54sheaths are used. This valve has only been used by a
retrograde approach—either via transfemoral, subclavian, or
direct aortic access.
A wide range of new devices has been tested with some
first-in-man experiences. These devices have been charac-
terized by smaller size, the ability to reposition or even
recapture the device after deployment if an optimized device
position is not obtained initially, and, modular prosthetic
elements to design in situ more optimal conformance to the
natural valve and aortic annulus among others.
Specific anatomic issues must be considered in device
design. These include the rigid structure of the pattern of
valvular calcification and aortic annulus, and the need for as
full apposition as possible to the annulus in an attempt to
minimize periprosthetic leak which, given sometimes eccen-
tric, bulky calcification, may be difficult. The close proximity
to the coronary ostia, the width and height of the sinuses,
the membranous ventricular septum with the His bundle
and the anterior leaflet of the mitral valve are also important
anatomical considerations. In addition, the size and degree
of severity of peripheral arterial disease are all factors that
could limit catheter size. Other issues include avoidance of
central prosthetic leak, leaflet durability, hemodynamic
performance, ability to treat both tricuspid and bicuspid
valve anatomy, surfaces designed to minimize thromboge-
nicity, and the need to optimally position the devices and
retrieve and reposition when necessary (94).
Fundamental issues for all current and future devices are
hemodynamic results, valve durability, and residual or new
aortic regurgitation (AR). The initial hemodynamic perfor-
mance of TAVR valves must be similar or superior to that
obtained with surgical AVR. This is crucial because high
residual transprosthetic gradients result in less symptomatic
improvement and poorer regression of left ventricular mass
(95). These transprosthetic gradients are a function of
Figure 2. CoreValve
The Medtronic CoreValve System is currently limited to investigational use in the
United States. Source: Medtronic, Inc.prosthetic size as well as the specific type of prosthesis and bcan result in patient–prosthesis mismatch. Typical immedi-
ate postprocedural gradients after surgical AVR range from
8 mm Hg to 12 mm Hg, whereas the AV area or effective
orifice area (EOA) ranges from 1.4 to 1.9 cm2. As docu-
ented below in the PARTNER trial, the valve hemody-
amics of the TAVR early on are approximately 10% better
han the specific surgical aortic prostheses used in that trial.
There are only limited clinical data on the durability of
AVR valves—up to 2 years—in the PARTNER trial and
p to 5 years in other registry experiences. Although the
bsolute number of patients is small, there have been no
eports of structural valve deterioration. The fundamental
linical need for durability may depend in part on the
pecific patient population. In the PARTNER trial, the
ean age at implant was 83 years, and serious comorbidities
ere frequent. In this setting, the need for durability of 20
ears is less important than if the patient selection criteria are
roadened to include patients in their early to mid 60s who
ave isolated AS without comorbid conditions. In this latter
roup, the TAVR valve must have at least equivalent clinical
urability to currently available surgically implanted valves.
4.3. Current State of the Evidence
4.3.1. Registry Experience
Registry data provide important information for assessing the
role of TAVR in a large number of patients who are not
eligible for randomized controlled trials because of strict
selection criteria. Several multicenter registries, including Ed-
wards Lifesciences and Medtronic CoreValve (Tables 1 and 2),
ave reported early and late outcomes with TAVR. How-
ver, patient selection criteria varied amongst the different
egistries; standardized definitions for clinical events such as
hose described by the Valve Academic Research Consortium
VARC) (96) were not used; and endpoints were not prospec-
ively adjudicated using a blinded clinical event committee.
CoreValve system real-world clinical experience to date is
omprised of multiple registries from several participating
ational sites (97,105–110,115). These study sizes range
rom 61 to 663 patients, with a combined clinical patient
xperience of nearly 2,350 patients that includes follow-up
f up to 2 years. (See Table 2 for details.)
4.3.1.1. DEMOGRAPHICS
Tables 1 and 2 summarize the major patient characteristics
or the Sapien and CoreValve family of registries, respec-
ively. The patients selected for entry are elderly (average
ge typically over 80 years), with symptomatic severe AS
mean gradient 45 mm Hg), significant comorbidities,
nd an average EuroSCORE of 23 (Sapien) and 16
CoreValve) (97,105–110), indicating a significant risk with
onventional AVR. However, unlike the PARTNER trial,
ll of these registries used the EuroSCORE risk prediction
ystem for defining high risk and inoperability. Euro-
CORE is generally not regarded as valid in high-risk
atients for surgical AVR, and surgeon input as to opera-
ility was not required in these registries. As a result, the
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March 27, 2012:1200–54 Transcatheter Aortic Valve Replacementregistry results are difficult to interpret because it is unclear
whether the patients who were enrolled in these registries
were truly “inoperable” versus “high-risk” (110,111).
4.3.1.2. OUTCOMES
4.3.1.2.1. PROCEDURAL SUCCESS AND HAZARDS. In the
OURCE (SAPIEN Aortic Biosprosthesis European Out-
ome) registry, procedural success rate (defined as 1 valve
mplanted, AR2, and patient left procedure room alive)
as 93% for transfemoral TAVR and 92% for transapical
AVR. The procedural success rate reported for CoreValve
s 92% except for 1 study that enrolled very high-risk
atients (105). Significant variations between registries were
Table 1. Edwards Sapien Transcatheter Heart Valve Registries
Characteristic
REVIVE, REVIVAL,
PARTNER EU
(N222)
SOURCE
Registry (T
(N920
Dem
ge (y) 83 82
emale (%) 55 56
uroSCORE (mean, %) 26 24
YHA functional class III/IV (%) 89 76
ortic valve area (cm2) 0.59 0.70
ean gradient (mm Hg) 45 49
rior CABG (%) 26 15
jection fraction (%) 51 52
Ou
0-day mortality (%) 10.4 7.5
-y mortality (%) 24 18.9
troke (%) 3.3 3.5
ajor vascular complications (%) 27.9 11.3
ermanent pacemaker (%) 1.8 6.7
CABG indicates coronary artery bypass graft; NR, not reported; NYHA, New York Heart Associat
Data are derived from the Edwards Lifesciences briefing document for the U.S. Food and
(http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/Medic
Table 2. Medtronic CoreValve Transcatheter Heart Valve Regis
Characteristic
Tamburino et al.
(109) (N663)
Milan (107)
(N61)
French (1
(N66
Dem
ge (y) 82 79 82.5
emale (%) 56 47 51.5
uroSCORE (mean, %) 23 26.6 24.7
YHA functional class III/IV (%) 71.5 69 74.6
ean gradient (mm Hg) 52 54 46
Ou
rocedural success (%) 98 98.4 92.6
0-day mortality (%) 5.9 2.2 15.1
-y mortality (%) 15 18.4* NR
troke (%) 2.5 2.2 4.5
ajor vascular complications (%) 2.0 21.3 7.5
ermanent pacemaker (%) 19.1 26.1 25.7*6-month survival, **2-year survival.
N indicates number; NR, not reported; and NYHA, New York Heart Association.ot observed in terms of deployment, relief of obstruction
nd avoidance of significant AR (110,111).
4.3.1.2.2. EARLY AND LATE MORBIDITY AND MORTALITY. The
early and late major outcomes with Sapien and CoreValve
registries are summarized in Tables 1 and 2. The early
morbidity of TAVR includes strokes, coronary occlusion,
pacemaker implantation, vascular complications, renal
failure, cardiac rupture and tamponade, bleeding, aortic
dissection, and death. The overall risk of any 30-day
major complication ranges from 20% to over 40%. Early
mortality ranges from an in-hospital rate of 5% to 8% and
a 30-day mortality rate from 8% to 10%. In the
SOURCE registry, the incidence of a major bleeding
France Registry
(N1,137)
Belgium Registry
(N303)
Canada Registry (TF)
(N162)
hics
83 83 83
49 46 44
23 29 26
75 80 93
0.67 0.60 0.63
48 47 48
19 20 30
53 50 55
s
7.8 8 9.5
NR NR NR
3.5 5.0 3.0
11.3 NR 13.1
8.5 4.0 3.6
TF, transfemoral.
Administration (FDA) Circulatory Devices Advisory Panel meeting on TAVR on July 21, 2011
esAdvisoryCommittee/CirculatorySystemDevicesPanel/ucm240575.htm).
Spanish (97)
(N108)
UK/Ireland (108)
(N288)
UK (115)
(N452)
German (110)
(N588)
Buellesfeld
et al.
(105)
(N126)
hics
78.6 81 81.3 81.4 81.9
54.6 NR 48 55.8 57.1
16 22 18.1 20.8 23.4
58.4 74 73.9 88.2 74.6
55 NR NR 48.7 46.8
s
98.1 97.5 98.2 NR 72.6
7.4 4.7 5.8 12.4 15.2
17.7 NR 21.7 NR 38.1**
0.0 4.2 4.0 2.8 NR
5.6 9.0 6.2 4.0 NR
35.2 26 24.4 42.5 26.2F)
)
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tcome
ion; andtries
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Transcatheter Aortic Valve Replacement March 27, 2012:1200–54event was significantly greater among patients undergoing
transapical versus transfemoral TAVR (3.9% vs. 2.3%),
whereas the incidence of vascular access-related complications
was significantly higher among patients having transfemoral
TAVR (major—11.3% vs. 2.0%; minor—10.4% vs. 1.0%)
(110–114).
Permanent pacemaker placement is reported in between
1.8% up to 8.5% of patients with Sapien and 19.1% to
42.5% with the CoreValve; renal failure in under 3%; and
stroke in 1% to 5%. Registry data reflect an overall mortality
rate at 1 year of 19% to 24%. In the SOURCE registry, more
than half (51.6%) of deaths up to 1 year had a noncardiac
etiology and were related to baseline comorbidities (110,111).
The recent UK TAVR Registry included 452 Medtronic
CoreValve implantations (115). In this group, standardized
data forms were used and audited. Procedural success was
achieved in 98.2% in this high-risk group of patients who
had a baseline logistic EuroSCORE of 18.1%. Thirty-day
mortality was 5.8%, and 1- and 2-year mortality was 21.7%
and 23.9%, respectively. In-hospital stroke occurred in 4%
of patients and myocardial infarction in 1.1%. A permanent
pacemaker was required in 24.4% (compared with 7.4%
with Sapien). Rates of moderate to severe postimplant AR
were 17.3% (compared with 9.6% with Sapien). Mortality
rates at all time points were significantly lower among
patients treated via a transfemoral route as compared with
nontransfemoral routes (85% transapical). In this study,
LV function, the presence of moderate/severe AR, and
COPD, but not vascular access site, were independent
predictors of mortality.
4.3.1.2.3. QUALITY OF LIFE IN REGISTRIES. Quality of life is a
ey patient-centered outcome. Although death is the lowest
ossible functional status, for many, survival marked by re-
uced physical function or independence may be worse than
eath. The PARTNER EU Registry is a multicenter study of
he early European experience in TAVR. Patients undergoing
AVR by transapical or transfemoral approach were followed
o 12 months for symptoms by New York Heart Association
NYHA) functional class, and heart failure–related quality of
ife as assessed by the Kansas City Cardiomyopathy Question-
aire (116). All patients improved, with no significant differ-
nces in NYHA functional class improvement noted between
ransapical or transfemoral approaches.
Several single-center registries have added additional
nformation on quality of life using disease-specific or
eneral surveys (Short Form-36 Health Questionnaire,
hort Form-12 Health Questionnaire, Kansas City Cardio-
yopathy Questionnaire, Minnesota Living with Heart
ailure Questionnaire) and on symptoms (NYHA func-
ional class, and 6-minute walk). Improvements following
AVR in vitality, physical functioning, and general and mental
ealth scores have been identified with physical function
emonstrating the greatest improvement. Patients who do not
xperience improvement are more likely to have comorbidities
hat contribute to continued symptoms and impair quality of
ife, such as COPD and reduced EF (Table 3).4.3.1.2.4. LEARNING CURVE. Each registry has identified a
rocedural learning curve, but the exact definition of this
urve and a clear method to decrease it are not yet clearly
eported. This curve has important components such as
atient selection, anesthesia, improvement in the equipment
ver time, and technical decision making regarding valve
eployment. The SOURCE registry enrolled 1,038 (Cohort
) and 1,306 patients (Cohort 2) undergoing TAVR pro-
edures over 2 sequential years. Age and EuroSCORE were
ot significantly different between the 2 cohorts. Compared
ith the first year of experience, valve malposition (1.6% vs.
.2%), and vascular access complications (2.1% vs. 1.8%)
ere not significantly lower in the second year. However,
eductions in the rates of postprocedure AR 2 (4.5% vs.
.1%, p0.011) and conversion to open surgery (3.7% vs.
.5%, p0.0315) were improved (110,111,121). Overall
0-day and 1-year survival was similar in both cohorts
espite higher number of patients with heart failure and
itral regurgitation enrolled in Cohort 2.
In summary, the registries demonstrate in high-risk
atients that TAVR may be deployed with a high degree of
rocedural success, predictable risk of stroke, device-
ependent high risk of pacemaker implantation (particularly
ith CoreValve), and a 30-day mortality rate that seems
otentially acceptable in a debilitated and ill patient popu-
ation. Importantly, TAVR seems to alleviate AS to a
imilar degree as surgical AVR and patients tend to return
o Class I or II symptoms with substantial improvements in
uality of life.
Future registries should be designed to include contem-
orary (i.e., VARC) definitions of procedural and quality-
f-life outcomes and utilize an independent clinical events
ommittee when possible to standardize event reporting.
onger-term follow-up studies are needed to demonstrate
he continued durability of TAVR in the high-risk and
noperable patients.
.3.2. Randomized Controlled Trial
4.3.2.1. PARTNER TRIAL DESIGN
The PARTNER trial (Figure 3) was a prospective, un-
blinded, randomized, controlled, multicenter pivotal trial
evaluating the safety and effectiveness of the Edwards
Sapien THV transcatheter aortic valve; 2 distinct popula-
tions were enrolled—inoperable, or Cohort B, and high-risk
operable, or Cohort A. Potential candidates were presented
on a national conference call for approval for treatment.
Randomization was stratified based on operability for AVR
surgery and within cohorts by vascular access for transfemo-
ral delivery. Patients who were considered high surgical risk
and eligible for transfemoral access were stratified into
Cohort A and randomized to treatment (transfemoral
AVR) or control (surgical AVR). Cohort A patients who
were not eligible for transfemoral access were evaluated as
candidates for transapical delivery and, if appropriate, ran-
domized to treatment (transapical AVR) or control (surgical
AVR). Nonsurgical candidates were stratified into Cohort B
ical fun
e repla
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trol (“standard” therapy). Inoperability was formally defined
as “50% predicted probability of mortality or serious
irreversible complication by 30 days by 1 cardiologist and 2
cardiothoracic surgeons” (15). Cohort B patients who did
not meet the criteria for transfemoral delivery were not
enrolled in the study because transapical delivery was
deemed too risky in Cohort B (Figure 3). Of the 3,105
patients screened, a total of 1,057 subjects (34%) were
enrolled at 25 sites in 2 arms—699 patients in Cohort A
and 358 patients in Cohort B. There were 2 co-primary
endpoints for the inoperable cohort: 1) freedom from death
over the duration of the trial with all patients followed for at
least 1 year from randomization; and 2) hierarchical com-
posite of death and recurrent hospitalization. In the high-
risk cohort, the primary endpoint was freedom from all-
cause death at 1 year. Prespecified secondary endpoints
included rate of death from cardiovascular causes, NYHA
functional class, the rate of repeat hospitalization due to
valve-related or procedural-related clinical deterioration, the
distance covered during a 6-minute walk test, valve perfor-
mance (assessed by echocardiography), and the rates of
myocardial infarction, stroke, acute kidney injury, vascular
Table 3. Quality of Life and Symptom Assessment in TAVR Reg
Study Population NYHA Functional Class
PARTNER EU Registry; Lefevre
et al. (Multicenter; N130
Sapien) (116)
Improved class at 1 year in 84.5%
of patients (85% NYHA
functional class III/IV at
baseline, 15% NYHA functional
class at 1 year); changes noted
at 30 days were sustained
Buellesfeld et al. (Multicenter;
N126 CoreValve) (105)
Improved in 80% at 30 days; 74%
at 2 years (in 50% by 1 level, in
20% by 2 or more levels)
Krane et al. (Single-center
registry; N99 TAVR) (117)
More class I/II at 3 months (NYHA
functional class III/IV from 98%
to 2% at 3 months)
Ussia et al. (Single-center
registry; N57 TAVR) (118)
More class I/II (average 1.8 NYHA
functional class improvement)
at 5 months (p0.001)
Bekeredjian et al. (Single-
center registry; N87
TAVR) (119)
Improved class (average of 1.7
NYHA functional class
improvement) at 6 months
(p0.001)
Gotzmann et al. (Single-center
registry; N44 TAVR) (120)
Decrease of percentage of NYHA
functional class III/IV from 90%
to 16% at 30 days
Im
BNP indicates brain natriuretic peptide; EQ-5D, EuroQol Five Dimensions; HF, heart failure; KCC
with Heart Failure Questionnaire; NR, not reported; NYHA, New York Heart Association; PF, phys
Questionnaire; SF-36, Short Form 36 Health Questionnaire; and TAVR, transcatheter aortic valvcomplications, and bleeding. All patients were followedduring the index hospitalization; at 30 days, 6 months, and
1 year; and yearly thereafter.
4.3.2.2. DEMOGRAPHICS AND OTHER BASELINE CHARACTERISTICS
The mean age was about 83 years in Cohort B and 84 in
Cohort A; slightly more patients were female (53.6%) in
Cohort B, and slightly more patients were male (57.2%)
in Cohort A; and most were Caucasian (Table 4). Over 92%
in both cohorts were NYHA functional class III or IV, and
60% of patients in both cohorts had undergone prior CABG
or PCI. Overall, the groups were balanced in most baseline
characteristics in Cohort A; however, there were some
imbalances in Cohort B (15). Patients in both cohorts had
relatively preserved LV systolic function.
Patients in Cohort B had greater frequency of coexisting
conditions that contributed to the surgeons’ determination
of inoperability, including an extensively calcified (porce-
lain) aorta (15.1%), chest-wall deformity or prior chest-wall
irradiation (13.1%), oxygen-dependent respiratory insuffi-
ciency (23.5%), and frailty, according to prespecified criteria
(23.1%).
4.3.2.3. PARTNER TRIAL RESULTS
In the inoperable Cohort B patients with symptomatic
es
nute Walk Questionnaire Other
NR KCCQ improvement at 1 year
in 72.7% (p0.0002)
Small improvement in
EQ-5D was not
significant
NR NR NR
NR Improved SF-36 PF general
health and vitality pre/
post at 3 months (all
p0.01). No change
mental health.
85% would do TAVR
again
NR SF-12; Improved (p0.001)
physical and mental
component scores, return
to population norms,
greatest change in PF
NR
NR SF-36 Improved physical and
mental component scores,
greatest change in PF
70% average decrease
in NT-proBNP levels
of 4,000 ng/L
(p0.0001)
ed walk time
t 30 days
MLHFQ; Improved HF-related
QOL
Lower average
decrease in BNP
levels of 400 pg/mL
(p0.005) and 25%
increase in 6-minute
walk time
(p0.005)
ates Kansas City Cardiomyopathy Questionnaire; LOS, length of stay; MLHFQ, Minnesota Living
ction; QOL, quality of life; SAVR, surgical aortic valve replacement; SF-12, Short Form 12 Health
cement.istri
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Q indicsevere AS, TAVR substantially reduced all-cause mortality
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Transcatheter Aortic Valve Replacement March 27, 2012:1200–54by nearly 50% and the composite of all-cause mortality and
repeat hospitalization by 55% compared with standard
therapy at 1-year follow-up (Table 5). In addition, all key
secondary endpoints including patient function significantly
improved at 30 days and 1 year. TAVR was associated with
an increased risk for stroke and procedure-related adverse
events such as bleeding and vascular complications. Sensi-
tivity analyses of patients as they were treated all favored
TAVR. Overall, the benefit from TAVR in inoperable
patients with symptomatic severe AS greatly exceeds the
risk.
In the high-risk Cohort A patients, TAVR was nonin-
ferior to AVR for all-cause mortality at 1 year (24.2% vs.
26.8%, hazard ratio: 0.93, 95% confidence interval: 0.71 to
1.22, p0.001 for noninferiority) (Table 6). AVR mortality
at 30 days (6.5%) was lower than expected operative
mortality (11.8%). Whether this discrepancy can be attrib-
uted to chance alone (ideal outcomes with expert surgeons
within the idealized environment of a randomized trial) or
due to “calibration drift” as surgical outcomes improve over
time is not clear. All neurological events (30-day major
stroke, 3.8% vs. 2.1%) and vascular complications (30-day,
11.1% vs. 3.2%) were more frequent with TAVR. By
contrast, major bleeding and new-onset atrial fibrillation
were more frequent with AVR. Improvements in echocar-
diographic findings were similar in both groups, although
paravalvular regurgitation was increased with TAVR. The
Figure 3. PARTNER Trial Designdata from this cohort further support TAVR as an accept- hable alternative to surgical AVR in selected high-risk
operable patients.
Of note, the 30-day mortality (generally thought to be
procedure-related) in Cohort A (3.4%) and Cohort B
(5.0%) was lower than the published SOURCE registry
mortality (8.5%), despite a relatively lower-risk patient
population enrolled in the latter (1-year mortality of 30.7%
in Cohort B, 22.2% in Cohort A, and 18.9% in SOURCE).
This arguably raises questions about the generalizability of
the randomized trial data to clinical practice.
4.3.2.3.1. QUALITY OF LIFE. The quality-of-life results from
ohort B arm, the inoperable cohort, TAVR patients had
mprovement in the 6-minute walk performance compared
ith baseline (p0.002), whereas standard therapy patients
id not (p0.67) (15). In addition, TAVR patients were
ess symptomatic (New York Heart Association class), had
educed hospitalization stay, and improved physical func-
ioning compared with standard therapy. In the high-risk
ohort, both New York Heart Association class and
-minute walk test favored TAVR at 30 days, but the
ifferences were not significant at 1 year. TAVR patients
ad shorter index hospitalization length of stay (8 vs. 12
ays, p0.001). Quality of life as assessed by disease-
pecific measures (Kansas City Cardiomyopathy Question-
aire [KCCQ]) and by general health-related quality of life
Short Form-12 Health Questionnaire) improved at 1, 6,
nd 12 months in the TAVR group and were significantly
igher than in the control arm (p0.001). This supports
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March 27, 2012:1200–54 Transcatheter Aortic Valve Replacementthat general and disease-specific quality of life are improved
with TAVR to 1 year over standard care among inoperable
patients (122) (Table 7). The quality of life results from the
Cohort A arm of the PARTNER trial were presented in
November 2011. The preliminary conclusions were that
among patients with severe AS who were at high risk for
standard valve replacement, both surgical and transcatheter
AVR resulted in substantial improvement in disease-specific
Table 4. Demographic and Other Baseline Characteristics of th
Characteristic
Cohort B
TAVR
(N179)
Standard R
(N179)
Dem
Age (y) 83.1 8.6 83.2 8.3
Male (%) 45.8 46.9
STS score 11.2 5.8 11.9 4.8
Logistic EuroSCORE 26.4 17.2 30.4 19.1
NYHA functional class III or IV (%) 92.2 93.9
O2-dependent COPD (%) 21.2 25.7
railty (%) 18.1 28
orcelain aorta (%) 19 11.2
hest wall radiation (%) 8.9 8.4
hest wall deformity (%) 8.4 5.0
Echocardiograp
V area (cm2) 0.6 0.2 0.6 0.2
Mean AV gradient (mm Hg) 44.5 15.7 43.0 15.3
Mean LV EF (%) 53.9 13.1 51.1 14.3
Cohort B includes only nonsurgical candidates in whom “inoperability” was formally defined as g
cardiologist and 2 cardiothoracic surgeons.
Cohort A includes patients determined to be at high operative risk defined as predicted operativ
f coexisting illnesses in order to predict 30-day operative mortality.
AV indicates aortic valve; AVR, aortic valve replacement; LVEF, left ventricular ejection fract
ranscatheter aortic valve replacement.
Data are derived from the Edwards Lifesciences’ briefing document for the U.S. FDA Circulatory
df10/P100041b.pdf) and may show some discrepancies compared with the published manus
Table 5. Major Outcomes at 30 Days and 1 Year in Cohort B o
Characteristic
30 Days
TAVR
(N179)
Standard
(N179
ll-cause death (%) 5.0 2.8
ll-cause death or rehospitalization (%) 11.2 12.3
vent-free MACCE (%) 90.5 94.4
All stroke (%) 7.3 1.7
Major stroke (%) 5.6 1.1
All-cause death or major stroke (%)* 8.4 3.9
Major vascular complications (%) 16.8 1.1
Major bleeding (%) 20.6 3.9
Pacemaker insertion (%) 3.4 5.0
Echocardiog
AV area (EOA) (cm2) 1.5 0.4 0.8 0.2
ean AV gradient (mm Hg) 11.1 6.6 33.0 12
Cohort B includes only nonsurgical candidates in whom “inoperability” was formally defined as g
cardiologist and 2 cardiothoracic surgeons.
*All-cause death or major stroke was not a predefined endpoint.
AV indicates aortic valve; EOA, effective orifice area; MACCE, major adverse cardiac and cere
Data are based on Edwards Lifesciences’ briefing document for the U.S. FDA Circulatory Devices A
pdf10/P100041b.pdf) , and may show some discrepancies compared with the published manuscriptsand generic health-related quality-of-life assessment over
1-year follow-up, including KCCQ Summary Scale, SF-12
Physical, and SF-12 Mental tests. The benefits were greater
at earlier time points in the transfemoral TAVR group and
were equivalent at 1 year (123).
4.3.2.3.2. CONTINUED-ACCESS PROTOCOL. Upon completion
of the randomized PARTNER trial, patients have been
allowed to have access to TAVR under a continued-access
RTNER Trial (Cohort B Data First)
Cohort A
p Value
TAVR
(N348)
AVR
(N351) p Value
hics
0.95 83.6 6.8 84.5 6.4 0.07
0.92 57.8 56.7 0.82
0.21 11.8 3.3 11.7 3.5 0.61
0.04 29.3 16.5 29.2 15.6 0.93
0.68 94.3 94.0 0.79
0.38 9.2 7.1 0.34
0.09 15.6 17.6 0.58
0.05 0.6 1.1 0.69
1.00 0.9 0.9 1.00
0.29 0 0.3 1.00
haracteristics
0.97 0.7 0.2 0.6 0.2 0.13
0.39 42.7 14.6 43.5 14.3 0.45
0.06 52.5 13.5 53.3 12.8 0.45
than 50% predicted probability of mortality or serious irreversible complication by 30 days by 1
lity of15% and/or an STS risk score of10%. The STS risk algorithm is based on the presence
HA, New York Heart Association; Rx, therapy; STS, Society of Thoracic Surgeons; and TAVR,
Advisory Panel meeting on TAVR on July 21, 2011 (http://www.accessdata.fda.gov/cdrh_docs/
PARTNER Trial
1 Year
p Value
TAVR
(N179)
Standard Rx
(N179) p Value
0.41 30.7 49.7 0.001
0.74 43.6 70.4 0.001
NR 65.4 47.1 0.003
0.02 11.2 4.5 0.03
0.04 8.4 3.9 0.12
0.12 33.0 50.3 0.001
0.0001 17.3 2.2 0.0001
0.0001 28.4 14.4 0.001
0.60 4.5 7.8 0.27
Endpoints
0.0001 1.6 0.5 0.7 0.32 0.0001
0.0001 12.5 10.3 44.4 15.7 0.0001
than 50% predicted probability of mortality or serious irreversible complication by 30 days by 1
ular events; NR, not reported; Rx, therapy; and TAVR, transcatheter aortic valve replacement.e PA
x
ograp
hic C
reater
e morta
ion; NYf the
Rx
)
raphic
.5
reater
brovasc
dvisory Panel meeting on TAVR on July 21, 2011 (http://www.accessdata.fda.gov/cdrh_docs/
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cohort was initiated following completion of the enrollment
for PARTNER cohort B trial. From March to September
2009, 91 inoperable patients were enrolled—41 were ran-
domized to TAVR and 50 to standard care. Both short-
term (30 days) and long-term (6 months to 1 year) results
have been reported (http://www.fda.gov/downloads/
AdvisoryCommittees/CommitteesMeetingMaterials/
MedicalDevices/MedicalDevicesAdvisoryCommittee/
CirculatorySystemDevicesPanel/UCM262935.pdf).
However, between-group analyses were not conducted due
to the small sample size. Enrollment in nonrandomized
continued-access cohort was initiated in September 2009
after both cohorts of PARTNER had completed random-
ized enrollment. Over 600 patients with transfemoral
TAVR are being followed currently in this cohort.
4.3.2.4. TAVR-SPECIFIC CLINICAL ISSUES
4.3.2.4.1. STROKE. Stroke is one of the major adverse events
associated with TAVR. Standardized criteria for the defi-
Table 6. Major Outcomes at 30 Days and 1 Year in Cohort A o
Characteristic
30 Days
TAVR
(N348)
Surgical A
(N351
Clinica
All-cause death (%) 3.4 6.5
All-cause death or rehospitalization (%) 7.2 9.7
All stroke (%) 5.5 2.4
Major stroke (%) 3.8 2.1
All-cause death or major stroke (%)* 6.9 8.2
Major vascular complications (%) 17.0 3.8
ajor bleeding (%) 9.3 19.5
trial fibrillation (%) 8.6 16.0
acemaker insertion (%) 3.8 3.6
Echocardiog
V area (EOA) (cm2) 1.7 0.5 1.5 0.
Mean AV gradient (mm Hg) 9.9 4.8 10.8 5.
Cohort A includes patients determined to be at high operative risk defined as predicted operative
of coexisting illnesses in order to predict 30-day operative mortality.
*All-cause death or major stroke was not a predefined endpoint.
AV indicates aortic valve; AVR, aortic valve replacement; EOA, effective orifice area; and TAVR
Table 7. Quality of Life and Symptom Assessment in TAVR Tria
Study Population NYHA Functional Class 6
PARTNER B (Trial) TAVR vs.
placebo (multicenter; N358)
(15,122)
More class I, II with TAVR
at 1 year (74.8% vs.
42.0%)
TAVR i
pre/
chan
grou
PARTNER A (Trial) TAVR vs. SAVR
(multicenter; N699) (124)
More class I, II with TAVR
at 30 days; No
difference between
TAVR and SAVR at
1 year
TAVR i
at 3
with
diffe
TAV
1 yeHRQOL indicates health-related quality of life; KCCQ indicates Kansas City Cardiomyopathy Question
replacement; and TAVR, transcatheter aortic valve replacement.nition of stroke endpoints for TAVR clinical trials have
been published by the VARC (Table 8). The incidence of
stroke depends on the assessment technique used for ascer-
tainment. In the PARTNER Cohort A, the risk of clinically
apparent “major” stroke defined as modified Rankin score
2 was 3.8% at 30 days and 5.1% at 1 year among the
TAVR group compared with 2.1% and 2.4%, respectively,
in the surgical group (124). In the PARTNER Cohort B,
the stroke risk was 5% with TAVR compared with 1.1%
with standard therapy at 30 days and 8.4% versus 3.9% at 1
year (15). Using magnetic resonance imaging-diffusion
weighted imaging (MRI-DWI) studies, the incidence of
cerebral ischemic lesions post-TAVR has been reported to
be as high as 68% to 84% in some studies, although
clinically apparent stroke was reported in 4% of cases
(125–128). Thus, the clinical significance of these new
CMR-defined lesions post-TAVR is not clear.
Most stroke cases are due to thromboembolism from the
valve site or due to atherothrombotic emboli originating
PARTNER Trial
1 Year
p Value
TAVR
(N348)
Surgical AVR
(N351) p Value
omes
0.07 24.2 26.8 0.44
0.24 34.6 35.9 0.73
0.04 8.3 4.3 0.04
0.20 5.1 2.4 0.07
0.52 26.5 28.0 0.68
0.01 18.0 4.8 0.01
0.01 14.7 25.7 0.01
0.01 12.1 17.1 0.07
0.89 5.7 5.0 0.68
Endpoints
0.001 1.6 0.5 1.4 0.5 0.002
0.16 10.2 4.3 11.5 5.4 0.008
ty of 15% and/or an STS risk score of 10%. The STS risk algorithm is based on the presence
catheter aortic valve replacement.
te Walk Questionnaire Other
ed walk time
t 1 year; no
no-TAVR
KCCQ; Marked improvement
with TAVR at 1 year;
SF12; improvement in
physical and mental
HRQOL with TAVR
TAVR had fewer
rehospitalizations at
1 year
ed walk time
s compared
; No
between
SAVR at
NR Shorter LOS with TAVRf the
VR
)
l Outc
raphic
4
0
mortalils
-Minu
mprov
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p
mprov
0 day
SAVR
rence
R and
arnaire; LOS, length of stay; NR, not reported; QOL, quality of life; SAVR, surgical aortic valve
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March 27, 2012:1200–54 Transcatheter Aortic Valve Replacementfrom ulcerative plaque in the great vessels such as the aortic
arch. Such particles can be dislodged during catheter ma-
nipulation and embolize to the carotids or vertebrals to cause
occlusions of distal intracerebral branch arteries. Other poten-
tial causes include hypotension associated with rapid ven-
ricular pacing or hemodynamic instability during the pro-
edure, and rarely due to aortic dissection complicating
AVR. It is important to recognize that many patients who
ave AS may also have other causes for an ischemic stroke
uch as age, hypertension, diabetes, or other cardiac condi-
ions, including atrial fibrillation, which is a potent risk
actor for cardioembolic stroke (69). Differentiating the
ause of the stroke is not always easy, but most trials and
egistries define strokes within 30 days of an interventional
rocedure as attributable to the procedure. After 30 days,
ther comorbid risk factors may account for stroke, which
ight, therefore, not be attributable to the prosthetic valve.
iagnostic evaluations are needed to assess the neck and
erebral vessels, cardiac function, and other potential causes
f stroke in order to differentiate the stroke subtype and
mbark on the best treatment to prevent a recurrent stroke
129,130). Nearly two thirds of the strokes related to TAVR
t 1 year occurred within the first 30 days in PARTNER
ohort B (13/20), suggesting that most events were likely
rocedure-related (15). The incidence of stroke may lessen
s patient selection becomes more refined, delivery systems
mprove in their profile, and embolic protection devices and
rotocol-driven antithrombotic regimens are routinely used
Table 8. Stroke
Stroke Diagnostic Criteria
Rapid onset of a focal or global neurological deficit with
hemiplegia, hemiparesis, numbness or sensory loss
hemianopia, amaurosis fugax, or other neurological
Duration of a focal or global neurological deficit 24 h; O
thrombolytic therapy or intracranial angioplasty); OR
infarct; OR the neurological deficit results in death
No other readily identifiable nonstroke cause for the clini
hypoglycemia, peripheral lesion, pharmacological in
Confirmation of the diagnosis by at least 1 of the followin
Neurology or neurosurgical specialist
Neuroimaging procedure (MR or CT scan or cerebral an
Lumbar puncture (i.e., spinal fluid analysis diagnostic o
Stroke Definitions
Transient ischemic attack:
New focal neurological deficit with rapid symptom reso
Neuroimaging without tissue injury
Stroke: (diagnosis as above, preferably with positive neur
Minor—Modified Rankin score 2 at 30 and 90 days†
Major—Modified Rankin score 2 at 30 and 90 days
*Patients with nonfocal global encephalopathy will not be reported a
†Modified Rankin score assessments should be made by qualified ind
the 30- and 90-day Modified Rankin scores, a final determination of
the clinical events committee.
CT indicates computed tomography; and MR, magnetic resonance
Reprinted with permission from Leon et al. (96).uring TAVR. 24.3.2.4.2. CONDUCTION DEFECTS. Atrioventricular conduc-
ion disturbances after TAVR are associated with many
atient-related and procedural-related factors, including
reoperative comorbid status, the degree and bulkiness of
ortic valve and annular calcification, interventricular septal
hickness, pre-existing electrocardiogram abnormalities, the
epth of prosthesis implantation, and the profile of the
mplanted prosthesis (131,132). Unlike conventional AVR,
here there may be localized trauma due to decalcification
f the annulus and/or suture placement in the proximity of
he AV node or the bundles, TAVR may cause conduction
bnormalities through mechanical impingement of the con-
uction system by the prosthesis.
The incidence of new left bundle-branch block and
omplete heart block after TAVR ranges from 14% to 83%
nd 19% to 22%, respectively. Patients with pre-existing
ight bundle-branch block may be at the highest risk for the
evelopment of complete heart block and the need for
ubsequent pacing (133). The majority of conduction ab-
ormalities occur prior to actual valve implantation, with
6% occurring during balloon aortic valvuloplasty, 25%
uring balloon/prosthesis positioning and wire-crossing of
he aortic valve, and the remaining 29% during prosthesis
xpansion (134). The incidence of complete heart block
equiring permanent pacemaker implantation has been
igher with the CoreValve (19.2% to 42.5%) than with the
apien valve (1.8% to 8.5%), potentially due to its larger
rofile and extension low into the LV outflow tract. In the
ost recent UK Registry, pacemakers were implanted in
t 1 of the following: change in level of consciousness,
ting 1 side of the body, dysphasia or aphasia,
or symptoms consistent with stroke
4 h, if therapeutic intervention(s) were performed (e.g.,
lable neuroimaging documents a new hemorrhage or
esentation (e.g., brain tumor, trauma, infection,
es)*
aphy)
cranial hemorrhage)
(usually 1 to 2 h), always within 24 h
ing study)
ke without unequivocal evidence based upon neuroimaging studies.
according to a certification process. If there is discordance between
ersus minor stroke will be adjudicated by the neurology members ofat leas
affec
signs
R 2
avai
cal pr
fluenc
g:
giogr
r intra
lution
oimag
s a stro
ividuals
major v4.4% of patients receiving the CoreValve.
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the CoreValve, but not Sapien valve, are higher than
conventional surgical AVR rates of 1% to 10%. The need for
permanent pacemaker implantation occurs early postproce-
dure and rarely after hospital discharge. The need for
permanent pacemaker implantation has no effect on sur-
vival, both early at 30 days postprocedure and late at 1 year
(135). Continuous postoperative electrocardiogram moni-
toring should be performed in all patients early after TAVR
procedures. Patients with pre-existing or new conduction
abnormalities and those receiving the CoreValve device may
require longer monitoring.
4.3.2.4.3. VASCULAR COMPLICATIONS. Vascular complica-
tions are the most frequent adverse outcome of TAVR and
are especially common with transfemoral approach (136).
These complications relate to the large-caliber sheaths
necessary for device deployment, as well as severe athero-
sclerosis of the arteries, which is common (137). Center/
operator experience, the degree and location of vascular
calcification, vascular tortuosity, and sheath-to artery ratio
are predictors of major vascular complication (137,138).
Major vascular complications are classified in accordance
with the definitions provided by the VARC and include
aortic dissection, perforation, rupture, or bleeding requiring
significant blood transfusions, or additional percutaneous or
surgical intervention (96). Incidence of major vascular com-
plications ranges from 2% to 26% with transfemoral access
and is related to vessel size, tortuosity, and degree of
aortoiliac occlusive disease and from 5% to 7% with
transapical access (107,109,111,116,139).
Subclavian access may represent an alternative approach
in some patients in whom transfemoral or transapical direct
aortic access cannot be utilized. Subclavian artery injury is
rare with such access although transient brachial plexus
neuropathy has been reported with this approach (140). As
delivery systems improve in their profile, the incidence of
these complications will lessen (136,141). Of note, left
subclavian arterial access for TAVR may not be appropriate
in patients with prior CABG with left internal thoracic
arterial graft because temporary interruption of blood flow
in the left internal thoracic artery may cause coronary
insufficiency.
4.3.2.4.4. PATIENT PREFERENCES. Informed consent requires
he patient and/or support system be appropriately informed
f the procedure benefits and risks, possess personal
ecision-making capacity, and ultimately be able to make a
oluntary decision. Older adults often rely on trusted
hysicians, family, or friends to participate and guide
edical decision making at the point of medical care. A
entral goal in this interaction is the exchange of relevant,
etailed information about treatment strategies delivered in
erminology that is understood by the patient and family.
his patient-centric educational effort is essential in provid-
ng the patient and family information to facilitate interac-
ion with the healthcare team, and promote personalized
ecision making for each patient. It is important to remem-er that risk tolerance and patient expectations vary across
any patient populations. Thus, a thorough review of
ersonalized risk/benefit profile is essential for each patient
ndergoing an invasive procedure.
4.3.2.4.5. BENEFIT/RISK ASSESSMENT. The complex task of
alancing the benefit and risk of TAVR depends upon
ccurate information regarding prognosis for survival, mor-
idity, and expected quality of life. Ideally, an accurate
alidated model that predicts both in-hospital and long-
erm outcome should guide this analysis, help educate
atients and their families, and effectively manage safety
radeoffs and healthcare expenditure. Such a model would
nclude some assessment of the relative role of severe AS
ersus comorbidity (e.g., COPD in the etiology of symp-
oms such as dyspnea). Although several risk models have
een developed for prognostication after cardiac surgery,
hey are limited by modest performance with regards to
iscriminatory ability, calibration, and face validity. It is not
lear whether these models for conventional cardiac surgery
re similarly predictive of outcome of patients being con-
idered for TAVR. An additional important issue relates to
he lack of a formal assessment of other aspects of treatment
isk and benefit (e.g., gait, cognition, frailty) in these risk
odels. Thus, better performing risk models are needed
hat include a wide spectrum of prognostic variables using
ontemporary data in relevant populations for a TAVR-
pecific risk algorithm.
In TAVR candidates, the benefits of avoidance of ster-
otomy and cardiopulmonary bypass with its attendant
omplications and prolonged recovery/hospitalization by
pplying TAVR appear to come at the price of potentially
erious vascular and technical complications and increased
azards of stroke and paravalvular AR (Figure 4). For
rohibitively high-risk inoperable patients, such a tradeoff is
Figure 4. Benefit/Risk Balance in the PARTNER Trial
Data are shown for every 1,000 patients treated with TAVR instead of standard
treatment in Cohort B (above) or standard AVR in Cohort A (below). The excesses
listed are not mutually exclusive, because some patients had more than 1 event.
Only data with statistically significant differences at 1 year of follow-up are shown
except for deaths* (p0.44) and atrial fibrillation† (p0.07) in Cohort A. AR indi-
cates aortic valvular regurgitation; AVR, surgical aortic valve replacement; and
TAVR, transcatheter aortic valve replacement.
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and clinically-important mortality benefit and functional
improvement. For high surgical risk patients in whom
mortality benefit has not been proven, the findings present
a dilemma, given that the irreversible effects of stroke might
be of greater potential clinical significance in terms of
long-term disability, permanent dependency, and increased
societal costs than the complications of sternotomy and
bleeding. Although bleeding occurs acutely, is often overt,
and has immediate clinical impact leading to increased
length of stay and resource utilization, a “causal link” to
adverse long-term clinical outcome remains unproven. Ul-
timately, the relative weights both patients and physicians
assign to the utility associated with these periprocedural
hazards is likely to impact individual case-based benefit/risk
assessment and decision making. Cost considerations are
also likely to materially impact the adoption of TAVR in
treatment algorithms for AS.
4.3.2.5. MEDTRONIC COREVALVE U.S. PIVOTAL TRIAL
The U.S. pivotal trial with the Medtronic CoreValve
self-expanding valve is currently enrolling patients at 40
sites (NCT # 01240902). Patients are allocated into either
an Extreme Risk cohort, similar to Cohort B inoperable
patients in the PARTNER trial or a High Risk cohort
analogous to PARTNER Cohort A. There will be 487
patients enrolled in the extreme-risk group with an addi-
tional 100 patients with inadequate iliofemoral access placed
in a nested registry of alternative access with either subcla-
vian or direct aortic approaches. The High Risk cohort will
enroll 790 patients in a 1:1 randomization between TAVR
and surgical AVR.
5. Integration of TAVR Into Clinical Practice
5.1. Patient Evaluation and Management
5.1.1. Multidisciplinary Team
The creation of a multidisciplinary team that includes the
patient in the decision process in choosing the most appro-
priate form of treatment for AS including AVR (i.e.,
surgical or percutaneous) is essential. It is similar in concept
to the “heart team” approach for CAD (142). Factors such
as sex, race, availability, experience, and institutional com-
mitment to managing very high-risk patients, technical
skills, local results, referral patterns, and patient preference
all may have an impact on the decision-making process and
should be taken into account by this multidisciplinary team.
Ideally, such a team would be comprised of the patient’s
primary cardiologist, cardiac surgeon, interventional cardi-
ologist, echocardiographer, imaging specialists—CT or
CMR, heart failure and valve disease specialist, cardiac
anesthesiologist, nurse practitioner, and cardiac rehabilita-
tion specialists. Such a strategy would result in input from
multiple skill sets with the goal being the best possible ecourse of therapy leading to the best possible clinical
outcome for the specific patient.
Localization of a heart team working together in a valve
clinic will help optimize the functions of the valve team.
Such a clinic should combine clinical cardiac care, advanced
imaging capability, and surgical consultation to provide
centralized assessment and treatment options for complex
valve disorders. Patients referred to a valve clinic should be
assessed by a cardiologist and a cardiovascular surgeon to
discuss the options for surgical intervention if indicated.
Prior diagnostic studies should be reviewed and additional
diagnostic imaging (echocardiography, TEE, MDCT
[multidetector computed tomography], CMR) performed
as clinically indicated. Overall, a valve clinic should offer
patients a personalized approach for the evaluation and
treatment of complex valve disorders with the availability of
a cardiologist and a cardiac surgeon specializing in valve
disorders.
5.1.2. Patient Selection
5.1.2.1. INCLUSION/EXCLUSION CRITERIA
TAVR is appropriate currently only for a highly select
population and the valve team should systematically identify
the characteristics that define that population with most
benefit and acceptable risk. These identification criteria
should be operationalized into practice and may evolve over
time with this new technology as new data become available.
The inclusion and exclusion criteria in extant randomized
studies are generally appropriate for use in clinical practice
(Table 9). These vary somewhat, but there are some criteria
common to most studies. Some criteria can be precisely
identified with objective measurements, but many require
subjective estimates based on clinical judgment. These
subjective assessments are at least as important as the
objective determinations and necessarily create some vari-
ability in the process of patient selection. The criteria
presented here are based on current technology and experi-
ence. As technology improves and experience is gained, it is
likely that many of these criteria will change to expand
TAVR to different populations that will be optimally
treated with the next generation of devices. In addition, the
arbitrary criteria such as qualifying aortic AVA measure-
ment within 45 days within the procedure will be modified
and made more flexible.
5.1.2.2. SPECIFIC PATIENT SUBSETS
5.1.2.2.1. PORCELAIN AORTA, FRIABLE AORTIC ATHEROMA,
ADIATION HEART DISEASE. Occasionally, otherwise fairly
ealthy candidates for AVR will have local factors such as
rior radiation therapy to their mediastinum and/or severe
alcific changes within their ascending aorta (“porcelain
orta”) that add significant risk to a traditional open AVR.
arely, transesophageal echocardiography will reveal ad-
anced atherosclerosis with mobile and pedunculated athe-
omata that also increase risk for stroke or a major embolic
vent with traditional TAVR. Cases such as these are
c
c
r
s
t
a
i
o
i
r
h
i
o
l
s
v
r
i
(
L
O
t
T
s
a
e
ardial in
; TIA, t
1220 Holmes, Jr. et al. JACC Vol. 59, No. 13, 2012
Transcatheter Aortic Valve Replacement March 27, 2012:1200–54approached individually and the correct approach is at best
an educated judgment on the part of the surgical team.
TAVR offers an alternative for the treatment of AS when
there is severe circumferential calcification (porcelain aorta) or
heavy atherosclerotic disease burden in the ascending aorta
(143). Patients with extensive atherothrombotic burden involv-
ing the ascending aorta should be approached very carefully
irrespective of whether either a transapical or transfemoral
procedure because of the potential for embolization.
5.1.2.2.2. VERY ELDERLY. Advanced age has important impli-
ations, as typically these patients have several comorbid
onditions (in addition to advanced age) that increase the
isk of AVR or TAVR. Functional status and comprehen-
ive assessment of comorbidities including CAD, history of
ransient ischemic attack or stroke, chronic kidney disease,
nd dementia should be performed. Finally, risk and benefit,
ncluding prognosis of existing conditions, should be thor-
ughly discussed with the patient and family as part of the
Table 9. Patient Selection: Inclusion and Exc
Inclusion Criteria
1. Patient has calcific aortic valve stenosis with echoca
jet velocity 4.0 m/s and an initial AVA of 0.8 cm2
measurement must be within 45 days of the date of
2. A cardiac interventionalist and 2 experienced cardiot
operation or are high risk for surgical AVR, based on
irreversible morbidity exceeds the probability of mea
specify the medical or anatomic factors leading to th
STS score to additionally identify the risks in the pati
physically evaluated the patient.
3. Patient is deemed to be symptomatic from his/her a
to comorbid conditions, and as demonstrated by NYH
Exclusion Criteria (candidates will be excluded if any o
1. Evidence of an acute myocardial infarction 1 mont
MI, or non–Q-wave MI with total CK elevation of CK-M
troponin level elevation [WHO definition])
2. Aortic valve is a congenital unicuspid or congenital b
3. Mixed aortic valve disease (aortic stenosis and aortic
4. Hemodynamic or respiratory instability requiring inot
assistance within 30 days of screening evaluation
5. Need for emergency surgery for any reason
6. Hypertrophic cardiomyopathy with or without obstruc
7. Severe left ventricular dysfunction with LVEF 20%
8. Severe pulmonary hypertension and RV dysfunction
9. Echocardiographic evidence of intracardiac mass, thr
10. A known contraindication or hypersensitivity to all an
the study procedure
11. Native aortic annulus size 18 mm or 25 mm as m
12. MRI confirmed CVA or TIA within 6 months (180 day
13. Renal insufficiency (creatinine 3.0 mg/dL) and/or e
of screening
14. Estimated life expectancy 12 months (365 days) d
15. Severe incapacitating dementia
16. Significant aortic disease, including abdominal aortic
cm or greater; marked tortuosity (hyperacute bend),
or ulcerated] or narrowing (especially with calcificatio
aorta, severe “unfolding” and tortuosity of the thorac
17. Severe mitral regurgitation
*The boundaries of annulus size will continue to change in concert
AVA indicates aortic valve area; AVR, aortic valve replacement; CK,
LVEF, left ventricular ejection fraction; MB, MB isoenzyme; MI, myoc
Association; RV, right ventricular; STS, Society of Thoracic Surgeonsnitial meeting with the TAVR team and should include a review of postprocedural complications that may extend
ospitalization. On the other hand, successful procedures result
n improvement in dyspnea, a heightened energy level, and an
verall improved quality of life. Life expectancy can be pro-
onged, since the mortality of medically-treated symptomatic
evere AS carries a high mortality.
As noted above, symptoms usually improve following
alve replacement, but a caveat exists for elderly patients
egarding dyspnea and the presence of LVH. LVH is seen
n 54% of men and 81% of women with severe AS
144–147) whereas men more often have less LVH, some
V chamber enlargement, and some reduction in EF.
ccasionally women will have such severe diastolic dysfunc-
ion that even when the afterload stress is relieved by
AVR, elevated LV filling pressures may result in persistent
ymptoms of shortness of breath. Since LVH may eventu-
lly regress following TAVR, shortness of breath may also
ventually improve over several months following valve
n Criteria in Clinical Trials
phically derived criteria: mean gradient 40 mm Hg or
dexed EOA 0.5 cm2/m2. Qualifying AVA baseline
ocedure.
ic surgeons agree that medical factors either preclude
clusion that the probability of death or serious,
l improvement. The surgeons’ consult notes shall
clusion and include a printout of the calculation of the
t least 1 of the cardiac surgeon assessors must have
alve stenosis, as differentiated from symptoms related
ctional class II or greater.
following conditions are present)
days) before the intended treatment (defined as: Q-wave
wice normal in the presence of MB elevation and/or
d valve, or is noncalcified
gitation with predominant aortic regurgitation 3)
upport, mechanical ventilation, or mechanical heart
s or vegetation
ulation regimens, or inability to be anticoagulated for
red by echocardiogram*
e procedure
age renal disease requiring chronic dialysis at the time
noncardiac comorbid conditions
racic aneurysm defined as maximal luminal diameter 5
arch atheroma [especially if thick (5 mm), protruding
surface irregularities) of the abdominal or thoracic
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anging device size.
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patterns (148), may have more inherent reduced contractil-
ity, so that relieving afterload with TAVR may also not
result in early or marked symptomatic improvement. When
discussing TAVR with the very elderly, they should be
made aware that symptomatic improvement may be delayed
or minimal in some cases.
5.1.2.2.3. FRAILTY AND FUTILITY VERSUS UTILITY. As previ-
usly discussed, the concepts of frailty and futility will
ssume central importance in patient selection for TAVR by
irtue of the extensive comorbidities present in this popu-
ation. Frailty is an important and frequent condition in
lderly patients and should be considered when dealing with
nvasive care in older adults (149). Although it can have
ignificant overlap with disability and comorbidity, it is a
istinct syndrome and is characterized by a vicious cycle of
ecreasing muscle mass, energy expenditure, and malnutri-
ion culminating in vulnerability to adverse events (150). In
he PARTNER trial, frailty was present in as many as 23%
f patients in Cohort B and 16% in Cohort A. Besides
omorbidities, and frequently in combination with them, it
s likely to play a role in the assessment of the individual’s
andidacy for invasive care and therefore in withholding any
ntervention in nearly one half of high-risk patients with AS
151). It is important to consider that frailty may be a
eversible physiological phenotype in some cases, and there-
ore it is premature to consider this a permanent character-
stic of the individual patient. To the extent that AS may
ontribute to the declining health state, AVR or TAVR
ay reverse frailty. In this case, frailty may be a marker for
reatment benefit. Conversely, if the individual is frail from
ultiple other organ system declines, frailty may be a
arker of treatment risk.
The impact of frailty on the clinical course and outcome
f patients presenting with severe AS is beginning to be
nvestigated but is difficult to assess because of its multidi-
ensional phenotype and the lack of a clear and agreed-
pon assessment. The definition of frailty used in recent
tudies ranges from the qualitative “eyeball test” to more
uantitative scores such as the Fried Frailty Index (150). A
imple test for defining frailty is a timed gait speed over 5 m.
n a recent Canadian study (152), a time of 6 seconds as
measure of frailty was found to be an independent
redictor of mortality compared with the STS risk algo-
ithm alone. As such, it has recently been added to the STS
atabase upgrade (Version 2.73, July 1, 2011) and will be
niformly collected in patients undergoing cardiac surgery
152). Future studies should aim at developing more reliable
nd reproducible ways of identifying frailty, as well as
ncorporating these assessments in development of risk and
enefit prediction.
Futility is also an important consideration for TAVR.
here may be some patients in whom this procedure should
ot be performed because the clinical condition is too far
dvanced; in these patients, even a successful technical
rocedure is futile and does not improve health outcomes. iTherapeutic futility may be determined based upon:
) lack of medical efficacy, as judged by the patient’s
hysician; or 2) lack of a meaningful survival, as judged by
he personal values of the patient (153,154). Although
herapeutic futility may be invoked to justify denial, limita-
ion, or withdrawal of care, the threshold for defining it is
nclear, controversial, and often viewed differently by dif-
erent stakeholders. In the PARTNER trial, the criterion
or inoperability—used as a surrogate for futility with
egards to surgical intervention—was an estimate of prob-
bility of death or serious, irreversible morbidity 50% by a
ardiologist and 2 experienced cardiothoracic surgeons (15).
espite successful correction of AS leading to an absolute
0% survival advantage, there was still 30% mortality in the
AVR treatment arm at 1 year, mainly due to noncardiac
auses. The key to treatment in this group of “inoperable”
atients is to define the “futility versus utility” treatment
aradigm. Clearer definition of comorbid conditions that
dversely affect survival despite successful valve implemen-
ation as well as quality of life and health economic
ssessment in those “inoperable” patients is crucial so that
his therapy is appropriately used in patients likely to benefit
utility) compared with those unlikely to benefit despite
uccessful therapy (futility). Although some might argue
hat it is inappropriate and misleading to say that treatment
s futile simply because the probability that it will succeed is
mall, especially given the substantial uncertainty in our
bility to prognosticate in individual patients and lack of
alidated tools that universally discriminate survivors from
onsurvivors of critical illness, it is nonetheless important to
efine meaningful cutoff points. This is particularly true
hen, in the course of a progressive illness, continued use of
esources other than measures for comfort, is no longer
easonable, practical, or appropriate. Ultimately, these de-
isions must be guided by what our society considers to be
he inherent value of human life and the resultant financial
urden society is willing to bear for the provision of modern
ublic health care (155).
.1.3. Care Plan in Candidates for TAVR
he healthcare team needs to be intimately involved in
iscussions on risk/benefits including detailed information
n individualized risks for each patient and alignment of
uality-of-life expectations. Failure to understand and com-
ly with a plan of care may account for dissatisfaction with
rocedural outcomes and potential rehospitalizations
156,157). One critical intervention to ensure effective care
oordination and transition is that of comprehensive plan of
are and educational material given to patient and/or care-
ivers prior to the planned procedures, and again during and
fter hospitalization. This process may encourage full par-
icipation of the patient and family about adherence to
edication therapy and activity recommendations. Transi-
ions of care and follow-up will be improved by discussion
nd written instructions reviewed with each patient includ-
ng medications, timely follow-up with the various health-
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and appropriate postprocedural activities. The ongoing care
and coordination with the cardiovascular care team may
decrease likelihood of readmission and improve overall
adherence. Healthcare providers should pay close attention
to psychosocial and socioeconomic issues that the patient
and family face, including access to care, risk of depression,
and healthcare disparities (158–160).
5.1.4. Imaging Assessment
Imaging plays an essential role in patient selection and
procedural planning, performance, and follow-up (161). In
each of these steps, optimal imaging can help to enhance
successful outcome. There is variability in the specific
imaging protocols preferred in individual institutions. This
variability is the result of institutional and individual expe-
rience and equipment, as well as the specific patient char-
acteristics to be considered.
5.1.4.1. ECHOCARDIOGRAPHY
The following general recommendations can be made for echo
assessment of patients being considered for TAVR. More
detailed instructions can be found in a recent expert consensus
statement from the American Society of Echocardiography
and the European Society of Echocardiography (161).
5.1.4.1.1. ANNULUS SIZE AND CUSP AND ROOT ANATOMY. Ac-
curate assessment of annular size is critical. Underestimation
of annular size could lead to selection and deployment of a
valve which is too small, with risks of poor hemodynamics,
paravalvular regurgitation, and valve migration and embo-
lism. Overestimation of annular size and placement of a
valve that is too large can lead to other adverse outcomes,
including incomplete deployment (with both valvular and
paravalvular regurgitation) or catastrophic annular rupture.
In general, all TAVRs are designed to be deployed in annuli
that are slightly smaller than the prosthesis size. This
oversizing is required because the valves are sutureless and
depend on radial force to prevent dislodgement. For the
initial Sapien valves, the 23-mm valve was designed for
18-mm to 22-mm annuli, whereas the 26-mm prosthesis
was designed for 21-mm to 25-mm annuli. The Sapien XT
valve, with 23-mm, 26-mm, and 29-mm sizes, is designed
for annuli from 18 mm to 27 mm. The CoreValve has
26-mm, 29-mm, and 31-mm prosthesis sizes (using a
different sizing convention from the Sapien valve) designed
for annuli from 20 mm to 23 mm for the 26-mm prosthesis,
24 mm to 27 mm for the 29-mm prosthesis, and 26 mm to
29 mm for the 31-mm annuli. Annular dimensions can be
measured with either TTE or TEE (162). With either
modality, the annular anteroposterior diameter is measured
from a long-axis view. Care must be taken to identify the
true annulus, not overlying calcium. Measurements are
made in systole at the hinge point of the leaflets into the
LVOT with a trailing edge to leading edge convention.
Because the annulus is often elliptical, optimal assessment
should include measurement of the transverse (coronal) tdiameter, using the short-axis view, ideally with biplane
TEE approach or CT, which allows simultaneous long- and
short-axis interrogation of the annular plane.
5.1.4.1.2. AORTIC ROOT DISEASE AND ASCENDING AORTIC DI-
ENSIONS. Assessment of cusp and root anatomy is also
critical. The PARTNER trial excluded all patients with
bicuspid aortic valves for concern that such valves might
distort the prosthesis, leading to paravalvular regurgitation.
Thus, TAVR in any nontricuspid valve would be considered
an off-label use, though successful treatment of bicuspid
valves has been reported (163). It is often difficult to
determine cusp anatomy in the densely calcified valves
commonly treated by TAVR. In this setting, CT or review
of old echocardiograms may allow better assessment of the
underlying anatomy. Pathology reviews have demonstrated
progressive increase with age in the proportion of trileaflet
valves in severe AS patients, from 15% in those under 60 years
to 60% over 70 years (72% for those over 80 years) (2). Of note,
this study showed that even pathological examination cannot
determine cusp anatomy in some heavily distorted valves.
Several issues must be considered in assessing root anat-
omy and pathology. Care must be taken to assure that valve
deployment will not compromise the coronary ostia, either
from the device itself or from cusp calcification being shifted
and displaced into the coronary. In general, CT scanning
provides a more comprehensive assessment of the relation-
ship of the coronary arteries to the annulus and valve
leaflets, demonstrating an average annular–left coronary
artery distance of 13.43.2 mm and annular-right coronary
artery distance of 13.62.8 mm (164). Nevertheless, echo,
particularly TEE, can measure the distance from the aortic
valve annulus to the right coronary ostium. Since the left
coronary does not lie in a standard TEE or TTE imaging
plane that intersects the annulus, measurement from 3D
datasets may be a feasible approach for this.
Accurate assessment of the aortic root and tubular por-
tion is also important. The CoreValve Revalving System is
designed with a supra-annular location of the porcine
pericardial valve, located in the sinus of Valsalva. As a result,
the CoreValve nitinol frame has a longer length than
conventional surgical valves, ranging from 52 mm ( for the
31-mm valve) to 55 mm (for the 26-mm valve) including its
deployment hooks. It is recommended that the upper
dimensions of the tubular aorta measured at 45 mm above
the annulus be 40 mm for the 26-mm valve and 43 mm for
the 29-mm and 31-mm CoreValve prostheses.
Preprocedural assessment of AR in TAVR candidates
should be governed by guidelines from the American
Society of Echocardiography (165). This assessment is
based on multiple parameters, including LV size, AR jet
size and morphology, AR pressure half-time, and diastolic
flow reversal in the aortic arch. Patients with3 AR were
excluded from the PARTNER trial and should be consid-
ered relatively contraindicated for TAVR.
5.1.4.1.3. THREE-DIMENSIONAL ECHOCARDIOGRAPHY. Real-
ime 3D TEE is an important modality for preprocedural
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(166,167). Similar to MDCT and CMR, it can help with
precise assessment of the aortic root and annulus, potentially
helping reduce the chance for prosthesis-sizing error in
patients. However, multiple studies have demonstrated
significant differences in dimensions of the aortic root and
annulus measured by 2D TTE, 2D TEE, 3D TEE, and
MDCT (166,167). Hence, it is imperative to realize that
the imaging technique utilized might impact TAVR size
selection and strategy. TEE, including real-time 3D TEE
can help evaluate the extent of and precisely locate the jet of
AR following prosthesis implantation.
5.1.4.2. TOMOGRAPHIC IMAGING
5.1.4.2.1. RATIONALE FOR TOMOGRAPHIC IMAGING. Opti-
mizing outcome relies heavily on image guidance for patient
selection, preprocedural planning, and intraoperative deci-
sion making (168). Correct positioning of the prosthesis
Table 10. Potential Approaches for Imaging in TAVR
Preprocedural Assessment
1. Assessment of aortic annular size and shape (CT, CMR, 2D and 3D echoca
2. Assessment of aortic valve for number of cusps, degree of calcification and
3. Measurement of the distance between annulus and coronary ostia (CT, CM
4. Planning for precise coaxial alignment of the stent-valve along the centerli
5. Assessment of aortic dimensions (2D and 3D echocardiography, CT or CMR
6. Assessment of dimensions and atherosclerosis of iliofemoral vessels (CT, M
Postprocedural Assessment
1. Assessment of degree of aortic regurgitation (echocardiography or CMR)
2. Assessment of cerebral embolization (cerebral MRI)
2D indicates 2-dimensional; 3D, 3-dimensional; CMR, cardiac magnetic resonance; CT, comput
Figure 5. Reconstructed Multidetector Computed Tomographic Im
Tortuosity and Extensive Calcific Atherosclerosis
The extent and degree of peripheral arterial disease is essential in determining the
ease, alternative approaches such as direct aortic, subclavian, or transapical procedures srelative to the annulus is critical. If valve deployment is
too high, increased risk of paravalvular regurgitation,
aortic injury, coronary occlusion, or embolization of the
prosthesis can occur. If positioning is too low, mitral
valve dysfunction, heart block, paravalvular regurgitation,
or embolization into the left ventricular cavity can occur
(169). In addition, the relatively large delivery catheters
currently required for valve insertion are associated with
the risk of vascular complications, necessitating assess-
ment of iliofemoral vasculature. This has led to the
application of 3D imaging approaches for TAVR, includ-
ing CT, CMR, 3D echocardiography, and C-arm CT
(162,166,170,171) (Table 10).
5.1.4.2.2. MULTIDETECTOR COMPUTED TOMOGRAPHY. MDCT
rovides comprehensive assessment of the aortic root, ath-
rosclerotic burden, and course of the thoracoabdominal
orta and its iliofemoral branches (Figure 5). MDCT in the
aphy)
area by planimetry (CT, CMR, 2D and 3D echocardiography)
and 3D echocardiography)
he aortic valve and aortic root (CT)
atherosclerosis (echocardiography, CT, or CMR)
giography)
ography; MRI, magnetic resonance imaging; and TAVR, transcatheter aortic valve replacement.
of the Abdominal Aorta and Its Pelvic Branches Demonstrating
lity and safety of transfemoral approaches. In some patients with extensive dis-rdiogr
valve
R, 2D
ne of t
) and
R, anages
feasibi
hould be considered.
1224 Holmes, Jr. et al. JACC Vol. 59, No. 13, 2012
Transcatheter Aortic Valve Replacement March 27, 2012:1200–54context of TAVR eligibility assessment has become routine
in many large-volume centers (172).
MDCT systems with at least 64 detectors and a spatial
resolution of 0.5 mm to 0.6 mm are recommended. The
specific scan protocols used for assessment vary but generally
include imaging of the aortic root and the thoracoabdominal
aorta and its iliofemoral branches. ECG-synchronized im-
aging of the aortic root is important to avoid image quality
degradation due to motion artifacts, and image reconstruc-
tion is performed at the desired phase of the cardiac cycle
(e.g., a systolic 30% to 40% phase for valve area and annular
assessment). Using the retrospectively ECG-gated helical
acquisition, CT data can be acquired throughout the entire
cardiac cycle, enabling 4D image reconstructions for evalu-
ation of valvular function, albeit at the expense of a higher
radiation dose (173). Alternatively, prospectively ECG-
triggered axial CT data acquisition requires much less
radiation; however, images are acquired during a prespeci-
fied phase of the cardiac cycle and reconstruction in other
phases or 4D cine loops may not be reconstructible (174).
However, protocols with newer generation scanners allow
prospective acquisition at a lower radiation dose with
subsequent display of cine loops (175). Although radiation
exposure is important to consider with any CT acquisition,
it is less a concern in the elderly patients currently consid-
ered for TAVR.
Because a standard bolus of 80 mL to 120 mL of
low-osmolar iodinated contrast is necessary, the benefits
versus risks of iodinated contrast need to be carefully
weighed (176). An alternative approach involves a pelvic
scan after intra-arterial contrast injection into the infrarenal
abdominal aorta (catheter left in place after cardiac cathe-
terization) using a very low dose (15 mL) of contrast (177).
If contrast administration is not feasible, a noncontrast scan,
although not optimal, still allows the assessment of overall
vessel size, calcification, and tortuosity.
As previously mentioned, analysis and measurement of
the annulus size and shape are crucial for procedural success.
Typical annulus measurements, obtained using 2D TTE or
TEE provide a single diameter measurement, assuming a
circular annular orifice (178). In contrast, 3D CT systolic
reconstruction of the annulus orthogonal to the center-axis
of the LVOT allows for the assessment of minimal and
maximal diameter, circumference, and area measurements
(162,164,166,179–183). Indeed, these studies have demon-
strated that the LVOT is often oval, rather than circular.
Hence, multimodality imaging might improve the accuracy
of AV measurements and reduce the chance for prosthesis-
sizing errors in patients considered for TAVR.
Complete coronary assessment with MDCT is obviously
limited in the current population evaluated for TAVR
because of the very high prevalence of advanced calcified
disease, precluding precise assessment of luminal stenosis.
However, MDCT allows measurement of the distance
between annulus and coronary ostia, which identifies pa-
tients at risk for coronary occlusion during TAVR. Al-though no definite criteria exist to exclude patients, a 10
mm distance might identify increased risk of coronary ostial
occlusion (184). In this setting, placement of a guidewire or
balloon catheter in the left main artery could be considered
to ensure access in case of complications.
Although echocardiography is used extensively to assess
the aortic valve, cine MDCT can provide incremental value
in its assessment, including number of cusps, especially in
cases of heavy calcification, where echocardiography can be
difficult. Also, cine MDCT can be used to perform planim-
etry of the aortic valve (180,185).
Optimal coaxial alignment of the stent valve along the
centerline of the aortic valve and aortic root is important
during positioning. Ascertainment of the right height to
avoid too high or too low placement is important to avoid
AR and optimize valve function (169). Although traditional
assessment of root orientation is performed using multiple
invasive aortograms in 1 or 2 orthogonal planes, double-
oblique multiplanar MDCT reconstruction allows prepro-
cedural prediction of the aortic root angle (186,187). This
potentially decreases the number of aortograms required
during the procedure, therefore shortening both procedure
time and contrast usage, and improves precision of deploy-
ment. The emergence of C-arm CT would further allow the
incorporation of fusion imaging in the catheterization lab-
oratory (170).
5.1.4.2.3. CARDIAC MAGNETIC RESONANCE. Similar to
MDCT, CMR can also potentially provide comprehensive
assessment of the aortic valve, annulus, aortic root, course of
the thoracoabdominal aorta and luminal caliber of the
iliofemoral branches, without the ionizing radiation. 2D
ECG-gated noncontrast cine CMR sequences across the
aortic valve (even avoiding the calcium blooming commonly
seen on CT) and aortic root can provide a detailed assess-
ment of LV function, aortic annulus, valve, root, and
coronary ostia, similar to that obtained on MDCT (188). In
addition, free-breathing noncontrast navigator-gated 3D
whole-heart acquisition can also be obtained to mimic the
volumetric acquisition of a CT image (171). It also enables
assessment of the aortic root in addition to assessing the
LVOT–aortic root angulation and predicting imaging
planes. The use of 3D gadolinium-enhanced magnetic
resonance imaging can provide precise luminal dimensions
of the thoracoabdominal aorta and its iliopelvic branches
(189). In cases with renal insufficiency, a navigator-gated,
free-breathing, 3D noncontrast steady-state free precession
sequence can be used to assess luminal dimensions. How-
ever, CMR is not optimal for assessment of aortic wall
changes, especially dense aortic calcifications, because it
would lead to signal voids and hence, appear dark. Postpro-
cedural assessment of residual aortic insufficiency by quan-
titative CMR might have a potential role in TAVR patients
(190). However, CMR is a time-intensive technique, which
could be a limiting factor, particularly in older patients. In
patients with tenuous renal function, the benefits of gado-
linium administration have to be balanced against the risks
1225JACC Vol. 59, No. 13, 2012 Holmes, Jr. et al.
March 27, 2012:1200–54 Transcatheter Aortic Valve Replacementof nephrogenic systemic fibrosis (191). In addition to the
above-mentioned constraints, CMR is not recommended in
patients with pacemakers, defibrillators, or intracranial an-
eurysm clips, although the currently used valves are CMR
compatible.
5.2. Procedural Performance
5.2.1. Role of Surgeon and/or Cardiologist
The central position of the heart team in optimizing TAVR
patient evaluation, procedure performance, and outcomes
has been emphasized. Candidacy for TAVR should be
determined together by both the surgeon and cardiologist,
ideally in an established valve or structural heart disease
clinic. During procedural performance, both cardiologist
and surgeon should be active participants. There are several
specific tasks to be considered among others: 1) gaining
access to the vascular tree by either various transarterial sites
or by the transapical route; 2) crossing the stenotic aortic
valve; 3) balloon aortic valvuloplasty; 4) optimal positioning
and deployment of the aortic prosthesis; 5) achieving secure
vascular closure; 6) assessment and treatment of procedural-
related complications, which encompasses vascular access,
cardiac structure, coronary artery anatomy, and electrophys-
iology issues; and 7) considerations for access for hemody-
namic support and the need for cardiopulmonary bypass
need to be determined by the cardiovascular (CV) surgeon
and team. Each of these tasks contains within it multiple
component parts, e.g., the need for rapid ventricular pacing
during either balloon aortic valvuloplasty or prosthetic
deployment, and identifying the optimal fluoroscopic posi-
tion to be used.
The above-mentioned tasks often require different skill
sets. In the future, as training programs evolve with inte-
gration of cardiovascular surgery and interventional cardiol-
ogy, the roles of either or both specialties may change.
However, at the present time and for the foreseeable future,
both a surgeon and an interventional cardiologist should be
integrally involved with each procedure. Prior to the start of
each procedure, a specific team leader should be identified,
either the surgeon or the interventional cardiologist. That
individual should have overall supervision for the specific
case to optimize the procedure. The specific person identi-
fied will depend on the operator experience as well as the
unique characteristics and challenges of each individual case;
for example, the cardiovascular surgeon should be the
primary team member responsible for the surgical aspects of
transapical and transaortic procedures or if a subclavian
cutdown is to be required. Interventional cardiologists
usually assume the lead operator position in transfemoral
procedures, whereas cardiothoracic surgeons usually lead
transapical procedures. The specific roles of the other
individuals involved should be identified. Some will be
shared, e.g., deciding what specific angle identifies the
optimal fluoroscopic view for visualizing the plane of the
aortic valve for deployment. Other roles will involve just 1individual, e.g., taking the team through the pre-and post-
procedure checklists and selection of the specific pacing
algorithm for deployment. It is important for all members of
the team to be present for all stages of the procedure.
The most important considerations are team-based care,
identification of a specific team leader, close communica-
tion, and preplanning for outlining management of poten-
tial complications. Likewise postprocedure care is optimally
delivered on a multispecialty team care service similar to a
transplant service where all specialties are participatory to
achieve optimal patient outcomes.
5.2.2. Procedural Location
Procedural location will vary from institution to institution
related to several factors including resources currently avail-
able in the facility. The specific location has important
physical implications, as well as personnel and equipment
implications. Optimal equipment requirements include a
state-of-the-art, large-field-of-view fluoroscopic imaging
system—preferably a fixed overhead or floor-mounted sys-
tem that has positioning capability rather than a portable
C-arm system. This system needs to have the ability to store
and review images and accommodate varying patient sizes.
A potentially important adjunct for this is the availability of
either biplane imaging or imaging programs that can auto-
matically help aid in the selection of orthogonal views for
imaging during positioning of the valve. Integration of TEE
echocardiographic images, particularly 3D capabilities, is
helpful; the availability of CT or CMR is a significant
advantage, particularly if image overlay is possible, which
will become more widely used in the future. Full catheter-
ization laboratory hemodynamic capability is also required
for hybrid rooms. Other resources required include present
cardiopulmonary bypass machines, perfusionists, and related
ancillary supplies with an inventory of interventional cardi-
ology equipment for balloon aortic valvuloplasty, coronary
balloons, stents, and 0.014-inch wires if coronary occlusion
occurs as a complication of device deployment. As vascular
access is critical, a variety of peripheral arterial balloons and
covered stents for treatment of peripheral vascular compli-
cations such as iliac rupture, and a variety of vascular closure
devices are also important for completion of the procedure.
The procedure location should also be fully capable of
providing anesthesia services including advanced airway
management, general anesthesia, full hemodynamic moni-
toring, and administration of vasoactive agents into the
central circulation.
As can be seen, these requirements mandate specific room
sizes and configurations. Such a hybrid room may be
situated in a surgical suite or may be in a large modified
catheterization laboratory (approximately 800 square feet)
with appropriate air handling and air exchange modifica-
tions. In the future, as procedures for the treatment of a variety
of structural heart and endovascular disease procedures in-
crease, it is anticipated that hybrid rooms will become more
standard of care for these team-based therapies.
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Personnel who are trained to deal with complicated hemo-
dynamics, the specific equipment to be used, and compli-
cation management are critical. This has significant impli-
cations. For example, if the procedures are carried out in a
modified cardiac catheterization laboratory staffed by car-
diac laboratory personnel, although there would be expert
experience with percutaneous procedures and vascular com-
plications, if urgent cardiopulmonary bypass was required,
there may be undue treatment delays related to inexperience
with that specific procedure. On the other hand, if the
procedures are carried out in an operating room with limited
catheterization laboratory capabilities and personnel, the
ability to promptly address and treat a coronary or a vascular
complication requiring immediate attention may be com-
promised. Team-based training and care that includes
complication management remain a cornerstone.
5.2.3. Anesthetic Considerations for TAVR
Patients undergoing TAVR are at a high risk for procedural
complications, including hemodynamic collapse. Careful
planning and intraoperative anesthetic management can
mitigate risk (67,192,193). During the preoperative evalu-
ation, special attention is paid to factors that may predict
higher risk of intraprocedural instability, in particular:
depressed EF, elevated pulmonary pressures, significant
MR, incomplete revascularization, collateral dependent cor-
onary circulation, COPD, HF, and acute/chronic kidney
disease. In patients least likely to tolerate rapid ventricular
pacing and hypotension, preventive measures may be insti-
tuted (194) and steps taken to allow for rapid institution of
cardiopulmonary bypass. Rarely, elective bypass may be
utilized. Routine surgical antibiotic prophylaxis adminis-
tered prior to surgical incision or vascular access is warranted
to decrease the risk of wound infection and endocarditis.
TAVR is typically performed under general anesthesia
with central monitoring, using a pulmonary artery catheter
and transesophageal echocardiography. Single-lung ventila-
tion is not necessary for TA procedures. Although a
temporary ventricular pacing wire can be placed through a
hemodynamic catheter, more commonly, a temporary trans-
venous lead is passed through the femoral or subclavian vein
or, in the case of transapical procedures, sewn directly on the
epicardial surface. After a ventricular wire is passed, thresh-
olds are checked at a pacing of rate 10 to 20 beats/min
higher than the patients intrinsic rates. For placement of the
CoreValve, rapid pacing for device placement is not re-
quired. Arterial pressure monitoring may be done via the
radial artery, but in the case of ipsilateral axillary bypass, a
plan must be made for additional monitoring either from
the contralateral radial or femoral artery. At least 1 large-
volume line is obtained peripherally or centrally. Immediate
access to a defibrillator device is necessary because ventric-
ular fibrillation can occur with manipulation of catheters
within the heart or with rapid ventricular pacing. This maybe best accomplished with preapplied defibrillator pads
connected to the defibrillator before starting the procedure.
Steps are required to prevent significant hypothermia,
and these are often similar to those used in off-pump
CABG. The room is heated, fluid warmers are used, and
some type of underbody heating system (either forced air or
fluid) is generally used. This is important because a limiting
step in early extubation of these patients is often the time
needed to warm them following the procedure.
Communication in this multidisciplinary approach is the
key word for intraoperative success. The importance of
training a dedicated team cannot be overemphasized. Fre-
quent changes of personnel will dilute the learning curve.
Standard doses of anesthetic, sedative, and narcotic analge-
sic agents may need to be reduced on the basis of the age
and frailty of the patient (195). Intraoperative challenges
may be encountered even before induction. Use of ultra-
sound for venous access is beneficial to prevent hemorrhage
and complications associated with placement of central line.
Unless otherwise indicated, volume status needs to be
supplemented as the patients in this age group are usually
volume depleted. Generally, 1.0 L to 1.5 L of fluid are
required, but a combination of pulmonary artery pressures,
central venous pressure, and echocardiographic evaluation
can guide tailored therapy. Severely underfilled ventricles
may pose an additional problem to guidewire/applicator
device insertion in these hypertrophied ventricles. Patients
with severe concentric LV hypertrophy and intravascular
volume depletion may exhibit a rapid and sustained deteri-
oration of hemodynamic status in response to ventricular
pacing, rapid ventricular pacing, intracardiac guidewire or
catheter manipulations, or balloon aortic valvuloplasty. In
patients with low cardiac output and those with more than
moderate PH, inotropes such as milrinone or dobutamine
may be considered prior to the procedure, with the goal of
obtaining a cardiac index of at least 1.8 L/min/m2. Inhaled
nitric oxide or inhaled epoprostenol should be available for
the treatment of severe PH and right ventricular failure.
Avoidance of prolonged hypotension is perhaps the most
important step in preventing hemodynamic collapse. The
cycle of hypotension, subendocardial ischemia, low output
and further hypotension with ultimate ventricular fibrilla-
tion is best avoided as treatment is difficult once these events
occur. Maintenance of a mean pressure of 75 mm Hg (or
systolic of at least 120 mm Hg) is advisable before initiation
of rapid ventricular pacing. The frequency and duration of
rapid ventricular pacing episodes may need to be limited to
allow enough time between episodes to permit recovery of
circulatory function in patients with limited hemodynamic
reserve. In patients with a slow recovery of spontaneous
circulation after ventricular pacing, pre-emptive therapy
with vasopressor therapy such as norepinephrine, epineph-
rine, or phenylephrine as an intravenous infusion or as
incremental intravenous boluses may be important to treat
hypotension and facilitate recovery after rapid ventricular
pacing. Hypertension may be dangerous and increase the
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Anticoagulation therapy is usually initiated after insertion
of the regular sheaths and prior to placement of the large
sheath into the vasculature, and repeated to maintain an
activated clotting time (ACT) of 300 seconds. Heparin
anticoagulation can be reversed by the administration of
protamine sulfate on a milligram to milligram neutralization
dose, although it may not be necessary to reverse heparin
anticoagulation for transfemoral TAVR if there is a minimal
risk of surgical bleeding. A transvenous pacing wire should
be secured in position in patients with postprocedural
interventricular conduction abnormalities, at high risk for
heart block, or with heart block until it is determined
whether a permanent pacemaker is necessary (196).
Although general anesthesia is generally used for
transapical procedures, some experienced institutions are
performing transfemoral implantation with conscious seda-
tion (197). With this approach, with conscious sedation, the
patient is awake and spontaneously breathing without an
artificial airway. Intraoperative TEE for procedural guid-
ance may be difficult or impossible if TAVR is performed
under conscious sedation. Adequacy of ventilation and
oxygenation should be continuously assessed during con-
scious sedation and qualified personnel and equipment to
perform intubation of the trachea, provide airway protec-
tion, and administer mechanical ventilatory support should
be immediately available to detect and treat acute respiratory
failure in patients managed during TAVR with conscious
sedation.
5.2.4. Vascular Access
Placement of TAVR is accomplished via femoral artery,
subclavian artery, or the aorta. The Sapien valve may be
deployed by major transvascular access as well as transapi-
cally, whereas the CoreValve uses only major transvascular
access (110). Careful evaluation of the patient’s atheroscle-
rotic load and location, arterial size and tortuosity, and
presence of mural thrombus are required for the best
possible delivery site. There are specific advantages and
disadvantages to each vascular access approach. Selection of
the optimal route requires consideration of specific patient
anatomy and the specific device to be used.
5.2.4.1. CARDIOPULMONARY BYPASS REQUIREMENT
Cardiopulmonary bypass is infrequently (5%) required for
support during the valve implantation due to cardiac de-
compensation as a consequence of cardiac tamponade,
coronary occlusion, severe acute AR, aortic rupture, or acute
aortic dissection. With experience, and excellent hemody-
namic and anesthetic management, this requirement is
rarely necessary. Accessory cannulation sites in the femoral
vessels or with an adjunctive axillary graft and venous cannula
should be considered if femoral access sites are not suitable.
Risk of vascular compromise, injury, or particulate embolism
should be weighed with the risk of cardiac support needs.5.2.4.2. PERCUTANEOUS OR CUTDOWN ACCESS
Both percutaneous and cutdown access approaches are used;
there are advantages and disadvantages to each. Complica-
tions with access in this high-risk and generally older
population are frequent. Decisions about access technique
and site depend on the degree and severity of atherosclero-
sis, vessel size, specific prosthetic device to be used, and the
heart team’s experience (136–138,198). Use of percutaneous
approaches preferentially occurs when access sites are rela-
tively large and free of significant atherosclerotic disease.
Less favorable vessels may require cutdown, often with
placement of axillary, iliac, or aortic insertion grafts or
conduits to provide access sites. Percutaneous insertions are
occasionally converted to open repair or hybrid repairs,
utilizing percutaneous closure devices and surgical tech-
niques as needed (199).
5.2.4.3. DEPLOYMENT TECHNIQUE
The goals of deployment are to avoid hemodynamic com-
promise while obtaining a stable valve, positioned without
coronary obstruction, interference of mitral valve function,
conduction system impingement, or overhanging native
aortic leaflets, and avoidance of aortic root complications
(rupture and dissection). There are several approaches to the
aortic valve, which can be broadly categorized as retrograde
or antegrade.
Retrograde passage is generally performed via the femoral
artery. There are obvious limitations in patients with pe-
ripheral arterial disease or small vessels. Additional, re-
ported retrograde options include the axillary approach and
direct ascending aortic puncture. A femoral approach is used
in the vast majority of retrograde deployments, starting with
either a standard percutaneous femoral arterial access or a
surgical exposure of the artery. A series of dilators is
employed, under fluoroscopic vision, to reach the size of the
deployment sheath. The sheath is passed into the body of
the thoracoabdominal aorta. Crossing the aortic valve is
accomplished using standard interventional techniques, and
a stiff wire exchange is performed, with redundancy in the
LV cavity to prevent loss of position. Care must be taken to
avoid damage to the LV, resulting in perforation.
The transapical approach is the only currently available
antegrade approach, and equipment is only available for this
approach for the Sapien valve. Access is obtained via a left
anterior thoracotomy, which is made after localization of
the apex by fluoroscopy or TTE. After entering the pleural
space, digital inspection can further localize the position of
the apex and a 2-inch to 3-inch segment of rib may be
resected to facilitate exposure. To reduce postoperative pain,
soft tissue retractors are preferred to heavy metal retraction.
The proper site of puncture is on the left ventricular apex,
which is more anterior and proximal than the anatomic
cardiac apex. TEE is of great value in helping to localize the
apex of the LV. Either 2 concentric purse-string sutures or
2 mattress sutures are placed with felt buttress. Puncture is
made and a 0.035-inch guidewire is passed through the
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placement by avoiding the mitral subvalvular apparatus.
After the guide wire is placed in the ascending aorta, a
coronary catheter such as a JR-4 can be used to guide the
wire into the descending aorta, and the wire is exchanged
for a stiffer wire (super or extra stiff). The deployment
sheath is then passed to a depth of 3 cm to 4 cm, following
which, balloon aortic valvuloplasty of the native valve is
performed prior to valve implantation.
A more recent approach that has gained interest and
acceptance is the direct aortic or transaortic approach. This
approach is being employed with both the balloon expandable
and self-expanding techniques. The access is through either an
upper partial sternotomy or a second or third right intercostal
space minithoracotomy. Concentric felt pledgeted rein-
forced purse-string sutures are placed in the ascending aorta
at least 5 cm above the valve. A guidewire is then placed
retrograde across the valve, and balloon aortic valvuloplasty
and valve deployment performed similar to the other access
techniques. The advantages of this approach include the
short distance from the aortic valve, allowing optimal
control and enhanced surgeon comfort level with a tech-
nique they are already using routinely for cardiopulmonary
bypass cannulation as compared with the left ventricular
apex approach. Another possible advantage is a less painful
incision than with a left anterior thoracotomy at a lower
interspace. Disadvantages include manipulation of the as-
cending aorta with possible embolization of atherosclerotic
debris when disease is present. Current-generation delivery
systems are being modified for this approach (200).
5.2.4.4. BALLOON EXPANDABLE VERSUS SELF-EXPANDING PROSTHESES
There are significant differences between the balloon-
expandable and self-expanding valves. Balloon-expandable
valves, such as the Sapien, cannot be collapsed once ex-
panded. Self-expanding, nitinol-based valves such as the
CoreValve can be partially deployed and repositioned to
some extent. The promise of recapture and repositioning
newer nitinol-based valves offer significant potential advan-
tages in reducing complications from malpositioning. Both
valves must be “oversized,” but the CoreValve in particular
seems to work best when the valve is somewhat underex-
panded. Risks of overaggressive sizing include leaflet dys-
function and annular or aortic rupture (110).
5.2.5. Imaging During TAVR
The mainstay of intraprocedural imaging is fluoroscopy and
angiography for device placement. TEE is an important
adjunct to this and is used at the operator’s discretion. The
role of intraoperative rotational CT scan is currently in
evolution. TEE is used for both transfemoral and transapi-
cal deployment, but with transfemoral procedures increas-
ingly being performed under local anesthesia combined with
conscious sedation (197), the role of TEE in this setting
may decrease, though imaging around the time of valve
deployment in this setting is possible (201) and transnasalTEE with smaller probes may allow prolonged monitoring
without general anesthesia, though clearly with significant
compromise in comparison to standard TEE. TTE may
also be used for guidance, though image quality is limited.
Similarly, intracardiac echocardiography has been reported
for TAVR guidance, though imaging capabilities are much
less than TEE (202). Personnel performing TEE guidance
of TAVR, whether cardiologists or anesthesiologists, must
be fully trained in the full spectrum of transesophageal and
intraoperative echo with special emphasis on the aortic valve
and associated structures (203). Training guidelines indicate
the need for involvement in 300 intraoperative studies, 150
as an operator (203). Additional training is necessary to
become familiar with the specifics of TAVR. Frequent
changes of the personnel performing TEE guidance dilutes
the learning curve and is not recommended. Patients under-
going TAVR tend to be elderly, unstable, and have multiple
comorbidities, and thus attention must not be diverted from
critical anesthesia management. It is possible for the attending
anesthesiologist to provide echocardiographic procedural guid-
ance, but in many situations, such guidance will need to be
provided by a dedicated cardiologist or anesthesiologist not
distracted by clinical anesthesia needs.
5.2.5.1. RECOMMENDATIONS FOR TEE GUIDANCE FOR PATIENTS
UNDERGOING TAVR
The following brief recommendations can be made for TEE
guidance of patients undergoing TAVR. More detailed
instructions of procedural echocardiography can be found in
a recent expert consensus statement from the American
Figure 6. Midesophageal Long-Axis TEE View Showing the
Proper Positioning of a Sapien Valve (black line*) Across the
Aortic Annulus Prior to Balloon Deployment
Note that approximately half the valve is above and below the annulus. Note also
the difficulty of imaging due to shadowing from the prosthesis and annular and
mitral valve calcification, as well as a prominent reverberation artifact, emphasizing
the need for thorough training prior to providing procedural guidance. LA indicates
left atrium. *Visible as black line.
amelio
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Echocardiography (161).
1. Guidewire placement: After confirming annular size for proper de-
vice selection, TEE can help with guidewire placement. This is
particularly important in transapical TAVR, where manual dimpling
of the apex can be visualized and guidewire passage through the AV
can be confirmed, avoiding the submitral apparatus or the hyper-
trophied septum.
Valve placement: TEE can be very helpful in the correct placement of
the valve prosthesis, though fluoroscopy is commonly used for
localization. It is critical to understand the landmarks of the valve
when mounted on the guiding catheter. For the Sapien valve,
roughly half of the device should be above and below the aortic
annulus (Figure 6). For the CoreValve, TEE should confirm that the
nitinol stent is well within the borders of the calcified native annulus.
Visualizing the valve during the time of rapid pacing and balloon
inflation (for the Sapien valve) or deployment of the CoreValve
provides an immediate verification of correct valve placement. If the
valve is placed using fluoroscopic guidance, the TEE probe must
be partially retracted during that time to facilitate positioning or the
fluoroscopic view can be changed.
2. Postdeployment assessment: A particular concern for periproce-
dural imaging relates to assessment of AR that is complicated by
the common frequency of paravalvular leaks and shadowing from the
prosthesis (Figures 7 and 8). This assessment must be made very
rapidly in the procedure room (to allow possible reballooning or
even deployment of a second valve if the AR is severe and cannot be
controlled otherwise). It is critical to distinguish between valvular
and paravalvular regurgitation and to determine whether it is severe
enough to require immediate intervention. Small paravalvular leaks
are often visualized due to the widespread irregular calcification in
the native valves that leave gaps between the annulus and the
prosthesis. If the leaks are punctate in cross section, with jets that
do not extend beyond the LVOT and without visible proximal conver-
gence zones above the prosthesis or flow reversal in the aortic arch,
Figure 7. Mixed AR
Central and paravalvular AR following TAVR deployment in a biplane long- and short-a
gitation, all of which are negligible. C is a more severe paravalvular leak, which was
left atrium; and LV, left ventricle.then no intervention is needed (Figure 7, jets A1 and A2). If not, andvelocity aliasing is seen superior to the prosthesis with AR extending
beyond the LVOT, then reballooning or a valve-in-valve approach
may be appropriate (Figure 7, jet C).
Mild central valvular regurgitation is commonly seen after valve
deployment, which frequently resolves with removal of the guide-
wire and/or a rise in central aortic pressure (Figure 7, jet B). An
inadequately deployed transcatheter valve may have crimped leaf-
lets with more significant valvular AR, which dictates reballooning.
Rarely, 1 of the leaflets may remain stuck in the open position,
resulting in torrential AR with marked aortic flow reversal and a
short pressure half-time (Figure 8) (204). In such a case, gentle
probing with a soft guidewire or catheter may free up the stuck
leaflet; if not, immediate placement of a second transcatheter valve
should be considered. This will be less of an issue with newer
generation valve designs.
Postdeployment echocardiography commonly discloses small ar-
eas of paravalvular or central valvular leak. Most commonly, these
originate around areas of extreme leaflet calcification, particularly
at the commissural areas. If significant, these may be treated with
repeat ballooning of the prosthesis to further expand it to close
paravalvular leaks or inadequate noncircular deployment. A small
additional amount of fluid (1 mL) may be added to the system prior
to reballooning to insure complete inflation (110,205–210). For
CoreValve, indications are similar—significant paravalvular leak
with AR and underexpanded prosthesis (assessed by TEE and/or
fluoroscopy).
There are a number of other complications that must be recognized
immediately after TAVR if poor clinical outcome is to be averted.
Persistent hypotension may result from occlusion of a coronary
artery by the device or displaced calcium. This can be recognized by
characteristic regional hypokinesis, best appreciated from the
transgastric view and possibly by evaluating flow in the coronary
arteries themselves. Global dysfunction with preserved coronary
flow may reflect persistent depression from rapid pacing and bal-
loon inflation, requiring inotropes and possibly intra-aortic counter-
E view. A1 and A2 are trivial paravalvular leaks, whereas B is a trivial central regur-
rated by a second valve inflation. Ao indicates aorta; AR, aortic regurgitation; LA,xis TEpulsation or full bypass. Finally, hypotension may result from LVOT
m
l
a
p
.
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negative inotropes, and vasopressors. Other etiologies such as
severe MR, dislodgement of the AV prosthesis, pericardial tampon-
ade, RV perforation from the pacemaker lead, air embolism, vascu-
lar access bleeding, and aortic dissection must be considered.
Although TEE is very helpful for initial device placement and deploy-
ment, it is in the setting of hemodynamic instability that TEE is
essential to rapidly diagnose these complications.
5.2.5.2. BALLOON DILATION AND SIZE
Prior to passage of the valve, predilation of the annulus is
performed. Standard techniques of percutaneous balloon
aortic valvuloplasty are employed, with rapid pacing during
inflation. Radiographic contrast opacification of the root
during maximal inflation may provide useful information
when the location of the coronary ostia in relation to the
annulus and the leaflet calcification or any other aortic root
pathology requires further delineation. The valvuloplasty bal-
loon size used is generally 20 mm to 23 mm, depending on the
size of the annulus (110,211,212).
5.2.5.3. RAPID PACING
Rapid ventricular pacing is generally required for deploy-
ments with balloon-expanding devices. The goal is to create
a transient reversible decrease in ventricular ejection,
thereby reducing forces leading to valve migration during
deployment. Typically, this requires pacing at a rate of 160
Figure 8. Severe AR
Long-axis TEE view showing severe AR following TAVR deployment (Panel A), confirm
D) demonstrates that this is due to failure of the leaflet in the left coronary position
one. Ao indicates aorta; AR, aortic regurgitation; LA, left atrium; and LV, left ventricleto 220 beats/min. Ideally, there should be a decrease insystolic pressure to 70 mm Hg, with a pulse pressure 20
m Hg. Pacing is accomplished by either transvenous or,
ess frequently, epicardial electrodes. Reducing the number
nd duration of pacing runs is important in this tenuous
atient population to prevent instability (110,213).
5.2.5.4. EXPERIENCE WITH TAVR
An important issue in evaluating the results of TAVR is
standardization of definitions for success, as well as efficacy.
The VARC Consortium has proposed the definitions for
device success, combined safety endpoint at 30 days, and the
combined efficacy endpoint at 1 year or longer (Table 11)
(96). Application of these standard definitions will facilitate
comparability and analysis of outcome between different
registries and studies. Another important issue on outcomes
as well as learning curves relates to the experience of the
center, patient selection criteria, and the expert onsite
technical support provided by the companies in each case.
For example, the UK TAVR experience documented similar
results with proctored and nonproctored cases, as well as the
first 20 cases versus continued cases in each center. This
finding must be considered in light of the fact that the
review of potential cases is influenced by the experience that
other operators and centers have gained. The presence of
the industry representatives in the procedures is also an
invaluable asset in recognizing the potential for complica-
ow reversal in the descending aorta (Panel B). Short axis imaging (Panels C and
) to close in diastole, ultimately treated by deploying a second valve inside thised by fl
(arrowtions and treatment of same. These 2 background issues
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the accelerated learning curve (115).
Compared with patients who underwent TAVR early
after its introduction, patients treated more recently have
benefited from shared experiences, more careful patient
selection, advances in equipment and technique, and ex-
panded operator experience. Prior reports have demon-
strated a steep learning curve with TAVR using the Cor-
eValve and Sapien valves (214–217). Whether improved
operator experience alone can improve certain outcomes
more than others remains unclear.
Since its introduction, increasing experience with the
CoreValve TAVR revealed a trend of improved combined
safety endpoint at 30 days from 30% to 17%, predominately
driven by a reduction in life-threatening periprocedural
bleeding complications occurring from TAVR (215). The
most recent UK experience (115) identified a 30-day mor-
tality of 5.8%. Furthermore, there was a significant reduc-
tion in cerebrovascular complications. Despite these trends,
all-cause and CV mortality at 1 and 2 years remain high.
Experience using the Edwards Sapien valve, on the other
hand, revealed that, in 1 analysis, procedural experience was
an independent predictor of 30-day mortality (214). The
overall combined 30-day mortality decreased with increased
experience, 10.5% to 8.5%. Procedural success rates also
improved from 92.6% to 97.8% with time, predominately in
the transfemoral approach, 89.3% to 98.8%.
Overall, consistent with other percutaneous therapies, the
evidence demonstrates that procedural success and mortality
rates improve with experience, whereas periprocedural com-
plications are reduced. The introduction of smaller valve
platforms introduces some uncertainty in defining whether
the improved outcomes are solely related to the operator’s
Table 11. Composite Endpoints
Device Success
● Successful vascular access, delivery and deployment
● Correct position of the device in the proper anatomic
● Intended performance of the prosthetic heart valve (a
mm Hg or peak velocity, 3 m/s, without moderate o
● Only 1 valve implanted in the proper anatomical loca
Combined Safety Endpoint (at 30 Days)
● All-cause mortality
● Major stroke
● Life-threatening (or disabling) bleeding
● Acute kidney injury—Stage 3 (including renal replace
● Periprocedural MI
● Major vascular complication
● Repeat procedure for valve-related dysfunction (surgi
Combined Efficacy Endpoint (at 1 Year or Longer)
● All-cause mortality (after 30 days)
● Failure of current therapy for AS, requiring hospitaliza
decompensation
● Prosthetic heart valve dysfunction (aortic valve area
velocity 3 m/s, OR moderate or severe prosthetic v
AR indicates aortic regurgitation; and AS, aortic stenosis.
Reprinted with permission from Leon et al (96).experience. Nonetheless operational volumes of given indi-viduals and centers are critical to consider. Current training
protocols attempt to accelerate the learning curve by utiliz-
ing experienced proctors and didactic teaching, represented
in both the PARTNER and CoreValve trials. If the
learning curve can be truncated, procedural outcomes may
continue to improve even as more operators enter this
clinical arena. Specific criteria regarding operator and center
training and experience are the focus of a multisocietal
credentialing document (218).
5.3. Complication Management
Complications with TAVR are fairly common due to both
the complexity of the procedure, as well as the morbidity of
the patients being treated (Table 12). This has led to
development of new tools and techniques to manage these
complications (219).
5.3.1. Shock, Low Cardiac Output Post-TAVR
The noncompliant hypertrophied ventricles in these pa-
tients are very susceptible to myocardial ischemia. The
combination of anesthesia, rapid pacing, volume shifts, and
brief periods of no cardiac output have made hemodynamic
shock and low cardiac output a not infrequent occurrence
during and immediately after deployment.
The need for careful management of systemic pressure,
inotropic support, and optimal ventilation to avoid and
mitigate PH is clear. In patients at extreme risk for
hemodynamic instability (i.e., those with low EF, collateral
dependent coronary circulation, or PH), elective cardiopul-
monary bypass (CPB) has been used to facilitate the
procedure. Not infrequently, IABP support may be required
to bridge these patients to adequate cardiac output. Also
rare, but reported, is occlusion of coronary ostia by deploy-
device and successful retrieval of the delivery system
tion
valve area 1.2 cm2 and mean aortic valve gradient, 20
re prosthetic valve AR)
therapy)
interventional therapy)
or symptoms of valve-related or cardiac
2 and mean aortic valve gradient 20 mm Hg or peak
R)of the
al loca
ortic
r seve
tion
ment
cal or
tion f
1.2 cm
alve Ament (approximately 1% of cases). These may be addressed
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brief periods to allow recovery. Using a combination of these
techniques, cardiac failure as a cause of death in TAVR has
been rare (109,220–224). Rarely, “suicide” LV can occur
and must be looked for. This occurs in patients with
combined AS and subaortic stenosis or severe LV hypertro-
phy and cavity obliteration (109,224,225). The situation is
exacerbated by diuresis and inotropes and is instead man-
aged with volume expansion and beta blockade.
5.3.2. Annular Rupture
Annular rupture is a rare but devastating complication of
TAVR. Predisposing factors include bulky and dense calci-
fication, small sinotubular junction, smaller annular size,
aggressive balloon predilation, and possibly porcelain aorta.
Once seen, mortality is high. Management can include
decisions for comfort care and sedation, attempts at medical
management with pericardial drainage and autotransfusion
of smaller leaks, and emergent conversion to open opera-
Table 12. TAVR Complications and Management
Complication
Management Options Depending on the
Clinical Condition, Hemodynamic Status, and
Number of Options Available
Shock, low cardiac output ● Careful systemic pressure management,
inotropic support, IABP, or CPB
Occlusion of coronary ostia ● PCI or CABG
Significant annular rupture ● Pericardial drainage, autotransfusion,
conversion to open surgical closure.
● If no other options, care and sedation
Ventricular perforation ● Pericardial drainage, autotransfusion,
conversion to open surgical closure.
Paravalvular aortic
regurgitation
● Postdeployment balloon dilation
Central valvular aortic
regurgitation
● Usually self-limited, but may require gentle
probing of leaflets with a soft wire or
catheter
● Delivery of a second TAVR device
Heart block ● Pacemaker implantation
Device malposition
Device embolization
● Deployment of overlapping 2nd valve
● Urgent endovascular or surgical management
Atrial fibrillation ● Rate control, rhythm control via
pharmacological or electrical cardioversion
Major ischemic stroke
Minor ischemic stroke
Hemorrhagic stroke
● Catheter-based, mechanical embolic retrieval
● Aspirin, anticoagulants
● Reversal of anticoagulation, correction of
coagulopathy
Major bleeding ● Hemodynamic support, blood transfusion
Vascular complications ● Urgent endovascular repair/surgery
Acute kidney injury ● Supportive care
● Maintain optimal fluid status
Each of the management options mentioned should be at least considered in the treatment of
these complications.
CABG indicates coronary artery bypass graft; CPB, cardiopulmonary bypass; IABP, intra-aortic
balloon pump; and PCI, percutaneous coronary intervention.tion, which makes it even more important to define and planfor or against this possibility in patients in a “high-risk”
substrate (226).
5.3.3. Post-TAVR Aortic Regurgitation
Post-TAVR AR must be characterized as to its location,
severity, and cause and should integrate both central and
paravalvular origins to estimate overall volumetric impact.
Central regurgitation is generally a result of improper valve
deployment or sizing. Heavy guidewires through the valve
can cause a substantial leak by holding a leaflet open, and
full evaluation of central leak can only be undertaken once
these wires are removed. Overhanging leaflet material can
change the diastolic flow pattern and lead to improper
leaflet closure. Damage to the leaflets can occur during
crimping; significant central AR requires rapid consider-
ation of a valve-in-valve deployment.
Paravalvular leaks of varying degrees are common. These
are generally caused by inadequate inflation of the prosthesis
or by calcific deposits that prevent the valve unit to properly
seat and seal within the annulus. Acute leaks may respond to
repeat ballooning the valve to obtain a better seal and more
expansion. Predisposing factors include eccentric calcifica-
tion and heavy irregular calcific deposits within the annular
area, and incorrectly sized prostheses. In addition, an
increased LVOT angulation in relation to the aorta, and a
valve seated less deeply in the annulus predispose to paraval-
vular leak. Paravalvular regurgitation is quite common imme-
diately post-TAVR, occurring at an incidence of 85%. At 1
year, up to 75% still have mild or more paravalvular regurgi-
tation, and one third have more than mild regurgitation.
The incidence of residual mild or moderate AR (1 and
2) is significantly higher in TAVR patients compared
with surgical procedures, whereas hemodynamically severe
postprocedural AR (3 and 4) is rare. Experience has
demonstrated that aortic paravalvular regurgitation after
self-expanding TAVR devices can be reduced by sufficient
balloon aortic valvuloplasty prior to deployment of a percu-
taneous prosthesis for self-expanding valves. Occasionally in
heavily calcified valves, repeat balloon dilation after valve
deployment is needed to fully expand the prosthesis. Post-
valve dilation can be performed safely with a slightly
oversized balloon, without causing significant structural
damage to the prosthesis. Appropriate preprocedural plan-
ning utilizing both echocardiography and CT for annular
analysis is important in order to avoid undersizing of the
valve compared with the annulus because this can also cause
significant paravalvular regurgitation.
Acute postprocedural regurgitation requires continued
surveillance because regurgitation may change in the subse-
quent days post-TAVR. The self-expanding properties of
the stent in the CoreValve prosthesis may reduce the grade
of paravalvular AR or recoil from the compressive forces of
the heavy calcification on either prosthesis may worsen the
degree (227,228). Clinical concern about the impact of
paravalvular regurgitation after TAVR is prudent, given the
findings that after surgical AVR, patients with moderate-
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can lead to left ventricular remodeling/dysfunction and
increase the risk for hemolysis. At the present time, there is
not sufficient long-term follow-up after TAVR to under-
stand the clinical significance of paravalvular regurgitation
and whether the severity of paravalvular regurgitation pro-
gresses with time. However, it is clear that postprocedural
regurgitation is associated with adverse outcomes (109,225).
There are no reported cases of hemolysis with TAVR
despite paravalvular AR.
5.3.4. Post-TAVR Heart Block
TAVR is associated with a variable incidence of complete
heart block and/or need for pacemaker implantation
(132,227–231). This is much more common in CoreValve
recipients (227–231). Preoperative conduction delay is asso-
ciated with an increased incidence of permanent pacemaker
implantation as well. Although heart block occurs usually early
after TAVR, it may be delayed up to 30 days. Enhanced
surveillance for this complication is important, particularly if
the patients are dismissed early following the procedure.
5.3.5. Post-TAVR Device Migration/Malposition
Rarely, TAVR devices will become malpositioned or mi-
grate. In the self-expanding models, they can be moved to
some degree until fully deployed. The balloon-expandable
models do not enjoy this degree of flexibility with position-
ing. A malpositioned valve may be “unstable” or may
embolize. If the valve is unstable, rapid placement of a
second overlapping valve may salvage the procedure. Valves
embolizing distally may occasionally be extracted in the
aorta and a second device implanted. Ventricular emboliza-
tion requires urgent surgery (185,232,233).
5.3.6. Ventricular and Vascular Perforation
Ventricular perforation is a rare complication of transfemo-
ral TAVR. Its management is similar to that for this
complication during percutaneous balloon aortic valvulo-
plasty, with pericardial drainage and autotransfusion or
conversion to open closure. Large-vessel aortoiliac injury
similarly is uncommon, but if present, can be managed in most
cases by introduction of a covered stent. Some operators place
a guidewire down the leg from the contralateral femoral artery
for rapid access and control. Readiness for vessel rupture with
occlusion balloon cannot be overemphasized. Preparation for
this complication is critical with preplanning. It is best man-
aged by avoiding it. Careful maintenance of a good wire
position and use of a stiff wire with a soft tip are helpful in
prevention of perforation during TAVR (234).
5.4. Postprocedural Care
5.4.1. Postprocedural Recovery
Designated units for postprocedural recovery are imperative
for optimal care and better outcome of this group of
high-risk patients undergoing TAVR (221). Although theparticulars of postprocedural care will vary from institution
to institution and country to country, as well as with the
maturity of the TAVR program, the principles of care
remain the same that these complex patients should be
treated in postprocedural units experienced with both car-
diac surgical and interventional cardiology procedures.
5.4.1.1. RECOMMENDATIONS FOR PROCEDURAL CARE AFTER TAVR
1. Immediate or early extubation, early mobilization, and meticulous
attention to the many potential complications in this elderly, frail
group of patients.
2. Post-anesthetic care unit (PACU) or intensive care unit (ICU). There
should be a common care pathway with all patients cared for in the
same setting so that the care team is conversant with the care
pathway. The criteria forweaning in a fast-track concept are as follows:
a. Adequate core temperature of 36°C
b. Hemodynamically stable
c. No active bleeding from drainage site
3. The care is somewhat different for transapical and transfemoral
patients. Prevention of postoperative hypertension and hyperten-
sion upon tracheal extubation is crucial in patients undergoing
transapical TAVR to decrease the risk of bleeding or ventricular
rupture. Patients undergoing transapical TAVR also require postop-
erative analgesia for thoracotomy incisional pain andmanagement
of thoracostomy tube drainage and subsequent thoracostomy tube
removal. Transfemoral TAVR patients require supine positioning
until femoral vascular access sheaths are removed and hemostasis
has been achieved. Patients undergoing direct aortic and subcla-
vian approaches also need to be carefully monitored for any
mediastinal/thoracic bleeding with particular attention paid to
avoiding postoperative hypertension.
4. The monitoring includes vital parameters including fluid balance
therapy, renal status, and atrioventricular conduction system. Ade-
quate hydration and avoidance of early diuretic administration is
important to minimize renal failure. Completion of perioperative
surgical antibiotic prophylaxis, resuming preoperative medications
such as beta blockers, and initiation of prophylaxis for venous
thromboembolism should be addressed within the first 24 hours
after operation. A pain management regimen should be initiated
immediately if necessary after operation in the postprocedural unit
and may consist of intercostal nerve block, infiltration of the wound
with local anesthetics, narcotics, or non-narcotic analgesics. Epidu-
ral analgesia is not normally required for transapical TAVR because
the thoracotomy incision is limited and satisfactory postoperative
pain control can be achieved with parenteral or patient-controlled
analgesics. Patients undergoing transfemoral TAVR should be eval-
uated for lower extremity vascular insufficiency, groin hematoma,
retroperitoneal bleeding, and femoral artery pseudoaneurysm for-
mation in the instrumented limb.
5. When stable, patients should be transferred to a telemetry unit with
hemodynamic and electrocardiographic monitoring capability. The
duration of monitoring will depend on the patients response to
TAVR and the specific prosthesis used. There are differences in the
need for permanent pacemaker implantation between the Edwards
Sapien and Medtronic CoreValve device with rates being lower with
the former; accordingly, longer electrocardiographic monitoring
may be required after implantation of the latter (132). Depending
on institutional protocols, patients should be discharged from the
hospital after a final examination with TTE. Antiplatelet therapy
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thrombotic or thromboembolic complications if there are no con-
traindications to these medications (235).
5.4.2. Hemodynamic Assessment
Echocardiographic assessment early after TAVR generally
reveals a favorable hemodynamic response, with the pres-
ence of a significantly lower mean transvalvular gradient and
a larger effective orifice area (EOA), usually 10 mm Hg
and1.5 cm2, respectively. Techniques used for assessment of
ortic valve performance vary. The use of measurements of the
eft of the LVOT diameter and velocity immediately proximal
o the stent has been emphasized (236). At short- and
ong-term follow-up, percutaneously implanted valves provide
ustained improvements in hemodynamic performance with
lightly lower mean transvalvular gradients and larger EOAs
han surgically implanted valves, either stented or stentless
237).
Postprocedure hemodynamic assessment is particularly
mportant to exclude potential prosthesis complications.
ranscatheter aortic valves differ, not only in design, but
lso in implantation technique from surgical AVR. TAVR
reserves the native calcified aortic valve compared with
urgical AVR, which requires that the native valve be
emoved prior to prosthesis implantation. The native valve
nd annular calcification may potentially prevent the adher-
nce of the prosthesis to the aortic wall, whereas low
rosthesis deployment into the LV outflow tract may lead to
ncomplete and/or irregular expansion of the prosthesis, as
ell as paravalvular prosthetic leak.
An additional concern is severe patient–prosthesis mis-
atch, which is defined as an effective orifice area index
0.65cm2/m2 (238). Patient–prosthesis mismatch in surgical
VR is associated with a reduction in functional status and
ncreased morbidity and mortality at short-term and long-term
ollow-up (239,240). The stent in TAVR prosthesis is thinner
han that of the stented valves employed for surgical AVR,
inimizing the obstruction to blood flow and reducing the
ncidence of patient–prosthesis mismatch. Whether reduced
ates of patient–prosthesis mismatch will translate to improved
unctional status and improved survival remains to be defined.
.4.3. Atrial Fibrillation
he incidence of new-onset atrial fibrillation (AF) after successful
AVR ranges from 0.6% to 8.6% (15,124,132,241). However,
ver 25% of patients undergoing TAVR have pre-existing
F. Continuous postprocedural electrocardiogram moni-
oring should be performed for at least 3 days in all patients
fter transcatheter therapy. Management of atrial fibrillation
ost-TAVR is based on the ACC/AHA/ESC guidelines
or management of atrial fibrillation (242).
.4.4. Treatment of Stroke
he treatment of a stroke will depend on the subtype of
troke diagnosed by brain imaging, timing of the event after
ny procedure, and the severity of the neurological deficit. Aarge intracerebral hemorrhage could call for reversal of any
nticoagulants and correction of any coagulopathy with
resh-frozen plasma or other transfusions (243). The diag-
osis of an acute ischemic stroke with moderate to severe
eurological deficits may require thrombolysis or mechani-
al clot retrieval depending on the size, location, and
hether any major intracerebral artery is occluded. An
n-hospital stroke within 8 hours of the onset of neurolog-
cal symptoms usually requires urgent consultation by a
troke neurologist or neurosurgeon. Angiography and stroke
ntervention may be recommended for large and/or dis-
bling strokes. These treatments are generally available at
omprehensive stroke centers. Typical embolic strokes in
his setting are the result of calcific emboli. If the stroke is
he result of thromboembolism, local rt-PA may be consid-
red although bleeding risk in this elderly population is very
igh.
Minor strokes, small infarcts on brain imaging, or the
bsence of any evidence of any major cerebral vessel occlu-
ions can usually be treated with aspirin (244). If atrial
brillation is present, then institution of an oral anticoagu-
ant program is warranted (129). If any intracardiac throm-
us is detected, then early institution of heparin followed by
ral anticoagulants is suggested (63). When the patient is
table, other diagnostic evaluations should be done to
valuate for other potential causes of stroke, including
ascular imaging to detect any extracranial carotid or verte-
ral stenosis or intracranial occlusive disease, echocardiog-
aphy, and Holter monitoring. If no definite source of
ardiac embolism is detected, then long-term treatment
ith antiplatelet options to prevent recurrent stroke may be
nstituted, which include aspirin, extended-release dipyrid-
mole, and clopidogrel (129).
5.5. Long-Term Care
5.5.1. Role of Primary Cardiologist
The long-term care of the patient after TAVR will be
mainly guided by the primary referring cardiologist. In
contrast to patients undergoing surgical AVR, patients
undergoing TAVR tend to be older, with more severe
comorbidities and lower functional status, mandating more
frequent cardiology follow-up.
The role of the primary cardiologist is to:
1. Prescribe and monitor medical therapy for concurrent
cardiovascular disease, including hypertension, atrial fi-
brillation, heart failure, CAD, and peripheral and cere-
brovascular disease, as well as diabetes and dyslipidemia.
2. Prescribe and monitor antithrombotic and/or antiplatelet
therapy as recommended for the prosthetic aortic valve
and concurrent conditions such as coronary stents or
atrial fibrillation.
3. Monitor cardiac and TAVR function with periodic
clinical evaluation and echocardiography.
4. Surveillance for and treatment of early and late
procedural-related complications
1235JACC Vol. 59, No. 13, 2012 Holmes, Jr. et al.
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physicians if complications occur that may be related to
the procedure.
5.5.2. Follow-Up Visits
The patient should be followed closely by the implanting
physician team for the first 30 days after TAVR to diagnose
and follow any procedural complications. Evaluations
should include a post-TAVR baseline echocardiogram and
ECG (to document any conduction abnormalities) occur-
ring during that time period. After 30 days, a suggested
schedule for follow-up by the primary cardiologist is noted
in Table 13.
Follow-up is then continued at the first 6 months, at 1
year, and annually thereafter. The frequency of follow-up
evaluations should be increased if there is significant post-
TAVR paravalvular leak or any change in clinical status or
echocardiographic findings. As experience grows with
TAVR, the frequency of echocardiography assessment will
likely decrease towards that of surgical AVR, deemed
appropriate every 3 years (245). Additional diagnostic stud-
ies may be considered as clinically warranted, including
evaluation for coronary disease if symptoms are present.
5.5.3. Hemodynamic Evaluation
Hemodynamic evaluation should be performed by echocar-
diography as indicated in Section 5.5.2 above. Invasive
measurement of LV and aortic pressure is not routinely
needed unless there are unresolved questions, discrepancies
between echocardiographic and physical examination find-
ings, or other unresolved clinical issues.
5.5.4. Interaction of Co-Treatments
Given the frequency of coexisting conditions, multiple
antiplatelet or anticoagulant strategies may be required. For
example, some patients may be receiving antiplatelet ther-
apy for a coronary stent or antithrombotic therapy for atrial
fibrillation. This is complicated by the fact that most
patients undergoing TAVR are elderly and often have
comorbidities that increase bleeding risk. It is prudent to
avoid, if possible, the use of multiple anticoagulant thera-
pies. In patients treated with warfarin, a direct thrombin
inhibitor, or Factor Xa inhibitor, it is reasonable to continue
low-dose aspirin, but other antiplatelet therapy should be
avoided, if possible.
Table 13. Recommended Patient Follow-Up Post-TAVR
Timing Post-TAVR Clinical Evaluation Echocardiography
30 days X X
6 months X
1 year X X
Annually thereafter X XTAVR indicates transcatheter aortic valve replacement.5.5.5. Management of AR
AR after TAVR typically is paravalvular and most often
only mild or mild to moderate in severity. At 1-year
follow-up, 13% of patients have no AR, with only trace or
mild regurgitation in 80% of patients (15,124). These
patients do not require any specific therapy for AR other
than medical therapy for concurrent hypertension and
periodic echocardiography monitoring as described above.
Moderate or severe AR is present after TAVR (even after
interventions during the procedure to reduce AR severity) in
about 12% of patients at 30 days and 7% at 1-year follow-up
(15,124).
5.5.5.1. RECOMMENDATIONS FOR MANAGING SEVERE AR AFTER TAVR
1. When severe AR is present after TAVR, treatment is similar to native
valve AR as detailed in the ACCF/AHA valvular heart disease
guidelines (63).
2. With acute severe AR or chronic severe AR with symptoms of heart
failure, surgical AVR may be considered if the patient is a surgical
candidate and surgical risk is acceptable. Other options include
placement of a second TAVR within the leaking prosthesis
(“valve-in-valve”).
6. Technology Evolution
Next-generation devices promise the potential for improve-
ments, offering expanded clinical utility with advances that
include: lower profile delivery catheters, more accurate
positioning, reduced paravalvular leak, and ability to either
reposition or even retrieve (Table 14) (246). Many of the
new device technologies utilize a self-expandable, high
radial strength repositionable prosthesis consisting of peri-
cardial tissue on a nitinol frame. Two additional valves have
recently received approval for commercial sale in Europe.
The JenaValve (JenaValve Technology, Munich, Germany)
and Acurate Valve (Symetis, Inc., Lausanne, Switzerland)
are both delivered currently via a transapical approach.
Other valve designs currently in early clinical studies
include Portico Valve (St. Jude Medical, St. Paul, MN),
Direct Flow Medical (Direct Flow Medical, Santa Rosa,
CA), and Sadra Lotus Valve (Sadra Medical, Los Gatos,
CA). Other new designs include flexible sealing membranes
aimed at more optimal conformation to the calcified native
annulus to reduce paravalvular leaks. New valve designs and
materials can also provide the possibility of new prosthesis
technology. The Lutter valve was created in an effort to
create a more physiological heart valve by utilizing tissue
engineering (247). The PercValve (Advanced Bioprosthetic
Surfaces, San Antonio, TX) uses nanotechnology in its
elastic nitinol frame and leaflets. These leaflets are designed
to allow for the growth of endothelial cells, essentially
converting it to a tissue valve. Initial animal studies have
shown complete endothelialization of the e-nitinol leaflets
within 10 days and may eliminate the need for anticoagu-
lation (248). A final novel approach involves anchoring the
prosthesis by using an injectable polymer that cures in
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outcome with these new technologies will be the focus of
multiple registries and then randomized trials.
7. Applications in New Patient Populations
and New Study Designs
As experience is gained and technology evolves, the patient
population best served with TAVR is likely to change, and
3 areas that merit specific consideration are the “valve-in
valve” technique for patients with dysfunctional aortic bio-
prostheses, the use of TAVR in patients with stenotic
bicuspid aortic valves, and application to lower-risk surgical
patients. Other patient populations, such as those with
chronic or end-stage renal disease, may also be candidates
for this technology and will be the subject of future
investigations.
7.1. Valve-in-Valve
Patients with dysfunction of a conventional aortic prosthesis
present therapeutic challenges. Although repeat operation
can be considered, an attractive option is to use a TAVR
procedure in which the device is deployed within the
previously placed bioprosthesis (209,249–254). In multiple
small series, transcatheter aortic valve-in-valve implantation
appears to be a safe option for the management of biopros-
thetic valve failure in patients at high risk for reoperative
conventional AVR. In this setting, coronary anatomy
should be carefully defined in order to minimize the
possibility of coronary obstruction by the transcatheter
prosthesis (209,220,250,255). In addition, valve-in-valve
procedures require a large enough bioprosthetic valve in-
serted at the index operation to prevent patient prosthetic
mismatch with the TAVR valve.
7.2. Bicuspid Aortic Valve
The asymmetric valvular anatomy often seen with a bicuspid
aortic valve theoretically predisposes to a noncircular expan-
sion of the TAVR device, thereby creating an increased risk
of paravalvular regurgitation (256).
Because of this concern, the presence of a bicuspid aortic
valve is considered a relative contraindication to TAVR.
Since bicuspid aortic valve patients have generally been
excluded from major TAVR trials, there is little clinical
experience in this area. Several centers, however, have
achieved reasonable success in selected bicuspid aortic valve
patients with AS (163,256,257). It should be noted that in
the Canadian bicuspid aortic valve experience, moderate
paravalvular leaks occurred in 2 of 11 patients, and another
patient experienced late device migration (256). Bicuspid
aortic valve patients with bulky leaflets, markedly asymmet-
ric valvular anatomy, and significant aortic incompetence
appear to have a higher risk of suboptimal device seating.
Whether new valve designs, perhaps those with self-sealing
membranes, will improve device performance in this group
remains to be determined.Ta Co
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Data from the STS Registry indicate that approximately
10% of patients undergoing AVR have an STS score 8
and therefore would be potential candidates for TAVR
using current selection criteria. There has been interest in
expanding the potential group of candidates for TAVR to
include patients with an STS score4. This would broaden
to 25% the number of patients who might be treated with
TAVR rather than AVR. There has been concern about the
potential for “selection creep,” with more lower-risk patients
treated with TAVR. This should be avoided until more
evidence-based data become available on the outcome of
TAVR versus AVR in these patients. The planned and
ongoing trials evaluating both the Sapien and the CoreValve
in lower-risk populations will be of central importance in
identifying subsequent utilization of this technology in
expanded patient groups.
8. Introduction of TAVR Into Practice:
U.S. Versus European Perspective
8.1. U.S. Perspective
The U.S. perspective reflects the fact that TAVR approval
required a randomized controlled trial, the full extent of
which has just now been published (124). This contrasts
with Europe where 5 new valves or iterations of current
valves are already in relatively widespread clinical use.
Accordingly, from the U.S. perspective, the rollout of this
technology is a key issue. This rollout is influenced by the
societal beliefs in a free market; convenient and timely
access to medical care; patient and physician expectations; as
well as return on investment by companies and institutions
alike. These latter issues have led to the proliferation of
advanced cardiovascular facilities, which could complicate
the rollout of new-device strategies such as TAVR. For
example, the state of California alone has 125 facilities that
perform percutaneous coronary intervention, the county/city
of Los Angeles has 33 cardiovascular surgical and primary
ST-elevation myocardial infarction centers. The Dallas–
Fort Worth Metropolitan region also has 33 full-service
cardiovascular surgical centers. To plan for each of these
centers in either Los Angeles or the Dallas–Fort Worth
region to offer TAVR would result in the dilution of
concentrated experience. Thus, for a complicated procedure
such as TAVR, which is applied in some of the highest-risk
patients treated for cardiovascular disease, such as those
enrolled in the PARTNER and CoreValve trials, setting up
specialized centers of excellence should be a top consider-
ation for optimizing patient care and outcomes.
The concept of development of these specialized heart
centers is likely to be somewhat controversial, given the
expectation in the United States that each hospital with
experienced personnel should be able to perform any and all
indicated procedures. However, results of TAVR are likely
to be optimal when performed by a heart team of experi-enced surgeons, structural interventional cardiologists, and
CV imaging specialists working together in high-volume
tertiary care centers with ancillary support services capable
of dealing with very complex patients with advanced comor-
bid conditions. For detailed recommendations, please refer
to the Multisocietal Position Statement on Operator and
Institutional Requirements for TVRR (218). The specific
details of the U.S. rollout and reimbursement for this
procedure are as yet to be fully determined. The criteria for
regulatory approval and reimbursement by appropriate fed-
eral agencies should be based upon expertise; high, adjudi-
cated procedure volumes; and documentation of a healthcare
team approach. In addition, mandatory enrollment in struc-
tural heart disease registries should be required so that short-
and longer-term outcomes can be assessed and updated with
new evolving data.
8.2. European Perspective
Adoption of TAVR has been rapid, and the changing trends
in Europe have escalated; in selected centers in Germany,
TAVR accounts for over 30% of all AVRs. For example, 1
single center has an experience of more than 1,300 TAVRs
and has trained more than 360 doctors in over 32 centers
from more than 30 countries. Germany itself has approxi-
mately 87 centers performing TAVR. The miniaturization
of the applicator device, the option to implant newer valves
from different manufacturers, and the need for high-quality
intraoperative imaging are challenges consistent with the
high costs involved with these procedures. Reimbursement
varies in different countries. In general, at present, the
insurance providers in Europe are bearing the high costs
involved in these operative procedures which may be ques-
tioned in the future, unless outcomes of improved long-term
survival are available. The United Kingdom approach to the
development of active TAVR centers has recently been
described and can serve as a model for other countries. This
rollout included 2 specific technologies (i.e., Medtronic
CoreValve and Edwards Sapien). The development of this
program consisted of didactic session, simulator training,
observation of cases at experienced centers, and proctoring
at new centers. Core essentials of the program included a
multidisciplinary team process for patient selection and for
procedural performance. All patients undergoing TAVR
were entered into a Central Cardiac Audit Database, which
included clinical as well as administrative data using stan-
dardized data elements and definitions. This approach has
the advantage of including all patients with either of the 2
devices, monitoring the potential of changing patient selec-
tion criteria, the ability to document learning curve and the
opportunity to evaluate the outcome of patients treated with
each of the devices. Particularly relevant findings include the
observation that: 1) 30-day and mid-term mortality was
equivalent in proctored and nonproctored cases; and 2) the
fact that outcomes in the first 20 cases were similar to
subsequent cases in each of the 25 centers involved.
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Post-marketing data collection for medical device evalua-
tion is an essential component in the assessment of device
performance and its benefit/risk balance throughout the
product life cycle. In addition to confirmation of data
observed in pre-approval studies, post-marketing studies
provide information regarding ‘real world’ use in patient
subsets not fully tested in pre-market clinical trials. Regis-
tries offer an important platform for post-marketing device
evaluation. For example, the STS National Database and
ACC’s National Cardiovascular Data Registry (NCDR®)
that have traditionally focused on national benchmarking,
quality improvement, and research, are rapidly emerging to
fulfill this important role. The ability to link clinical registry
data with administrative data opens an untapped resource
for monitoring and predicting both short- and potentially
long-term outcomes. In general, the short-term clinical
information can be used for risk stratification and identifi-
cation of important clinical subgroups, whereas the admin-
istrative data can be used to track patterns of use and
ultimately long-term events.
In the past, device monitoring has typically been carried
out through industry-supported trials and post-approval
studies. It has been necessary for industry to undertake the
very expensive and time-consuming task of developing data
registries. In the development of these registries, there has
been little coordination with existing societal registries to
harmonize definitions or data specifications. An unfortunate
byproduct of this approach has led to the well-recognized
inconsistencies seen in cardiovascular data reporting. In
addition, there is the unavoidable potential for a conflict of
interest that might arise from a manufacturer conducting
studies of its own device.
The use of clinical registries can address many of these
concerns. Registries such as the STS Database and ACC’s
NCDR® have a high degree of national participation, so the
data represents a true national experience. These registries
have a well-established protocol for data collection, with
trained abstractors and onsite rigorous audits to ensure high
data quality and completeness of entry. Database definitions
are generally regarded as national standards, and there is a
high degree of harmonization between terms common to
these registries. These definitions should be based upon
consensus documents; for example, VARC definitions of
stroke (96). Furthermore, each registry can be linked to
administrative databases in order to obtain long-term out-
come information. These facts demonstrate the ability of
the national cardiovascular registries to serve as the founda-
tion for comprehensive device registries. In the last few
years, the FDA has collaborated with various organizations
to use registry data to investigate several important device-
related studies. Although there is no specific legislative man-
date to use clinical registries, FDA leadership does actively
encourage the use of registries for device surveillance.Registries offer distinct theoretical advantages in this
field, but it should be remembered that practical application
presents unchartered waters. Perhaps 1 major challenge lies
in the fact that a successful program will require close
cooperation between multiple organizations. For example,
the STS and ACCF have a long history of cooperation and
collaboration on registry-related projects, holding monthly
conference calls devoted to registry coordination, thus laying
the foundation for collaborative projects such as device
surveillance. Similar collaborations will require the need for
contractual agreements to address issues such as data own-
ership, data access, and governance of linked registries.
Sophisticated statistical analysis will be a central feature of
surveillance projects, so coordination with an analytic center
will also be necessary. Certainly, FDA input will be central
to any device-related project, and coordination with the
Centers for Medicare and Medicaid Services (CMS) may be
necessary as well. The device manufacturer will have an
essential role, especially in post-approval studies, so coordi-
nation with industry will be a key element of any project.
Device surveillance will require fundamental changes in
the clinical database operations. Presently, there is no
provision for timely data entry, but post-approval studies
will require exactly that in order to capture adverse events as
they occur. Likewise, post-approval studies require long-
term follow-up of information that cannot be obtained from
administrative databases. Provision must be made to capture
information such as echocardiographic findings and quality-
of-life data months to years after device insertion. It should
also be noted that the use of CMS MedPAR data may have
limited usefulness in this context because of the inability to
acquire contemporary data limited to only those patients
65 years. (In general, the most current available MedPAR
data are 2 years old.) Additional challenges include standard-
ized rigorous methodology adapted for sparse data and stan-
dardized reporting formats modeled after the CONSORT
(Consolidated Standards of Reporting Trials) guidelines for
randomized trials, PRISMA (Preferred Reporting Items for
Systematic reviews and Meta-Analyses) guidelines for meta-
analyses, or STROBE (STrengthening the Reporting of
Observational studies in Epidemiology) guidelines for ob-
servational studies (182,258–260). It should be emphasized
that the registry should capture data on all devices that are
placed. Specific post-approval studies may focus on a
smaller, more select population, but a comprehensive reg-
istry should collect information on all devices for complete
analyses independent of industry-sponsored studies. A po-
tential incentive for participation in the device registry
might be linking it to CMS coverage criteria or other form
of federal legislation.
Funding the device registries requires innovative consid-
eration. Despite the fact that federal agencies encourage the
use of clinical registries, funding for such projects is not
available for device-related projects. Although industry
funding for studies related to their specific product offers the
SM
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centers to pay a fee in return for registry participation.
As registries are developed, a “silo” construction must
be avoided. It is critically important to keep an eye on the
future so that present plans fit seamlessly with the vision
for future initiatives. This means that a device-specific
registry should be designed to serve as a building block
for the next generation of registries. Planning for in-
teroperability, resource sharing, and avoidance of dupli-
cation will be necessary to create the system of integrated,
coordinated registries that will be the hallmark of regis-
tries for the next decade.
10. Summary and Recommendations
There are a number of potential treatment recommenda-
tions for patients with AS (Table 15). Consideration of the
risk/benefit of each option needs to be carefully evaluated
Table 15. Current Treatment Recommendations for Patients W
Treatment Indicatio
urgical Aortic Valve Replacement ● Symptomatic severe AS (Class I, LO
● Severe AS undergoing CABG, aortic
(Class I, LOE: C)
● Symptomatic moderate AS undergo
other valve surgery (Class IIa, LOE:
● Asymptomatic severe AS with hypo
(Class IIb; LOE: C)
● Asymptomatic extremely severe AS
gradient 50 mm Hg, or jet velocit
Transcatheter Aortic Valve
Replacement
● TAVR is recommended in patients w
calcific stenosis of a trileaflet aortic
vascular anatomy suitable for TAVR
12 months, and who have a proh
by an estimated 50% or greater ris
morbidity at 30 days or other facto
radiation therapy, porcelain aorta, a
pulmonary disease.
● TAVR is a reasonable alternative to
high surgical risk (PARTNER Trial C
Balloon Aortic Valvuloplasty ● Reasonable for palliation in adult p
surgical AVR cannot be performed
conditions (Class IIb, LOE: C)
● Bridge to surgical AVR (Class IIb, LO
edical Therapy ● No specific therapy for asymptoma
● Medical therapy not indicated for s
● Appropriate control of blood pressu
indicated
● Statins not indicated for preventing
● Diuretics, vasodilators and positive
in patients awaiting surgery becaus
Class I: Conditions for which there is evidence for and/or general agreement that the procedure o
and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment; Class
well established by evidence/opinion; LOE B: Data derived from a single randomized trial or nonr
original PARTNER protocol specified inclusion criteria as a minimum STS-predicted risk of mortal
to 8. In both instances, 2 surgeons had to document that the true predicted risk of mortalityAR indicates aortic regurgitation; AS, aortic stenosis; AVR, aortic valve replacement; CABG, corona
ranscatheter aortic valve replacement. Source of Class/LOE recommendations: Bonow et al. (28).and discussed with the patient and family. The involvement
of the heart team in decision making is also essential.
The approval of TAVR represents a fundamental change
in the management of aortic valvular heart disease by
offering an alternative to traditional surgical aortic valve
replacement in carefully selected patients. The penetration
of this technology in the broad group of patients with AS
remains to be determined and will depend on the continued
evolution of the technology and the results of clinical trials
conducted in these patients. At the present time, several
observations and recommendations can be made.
1. Complex Technology: Although the technique and equip-
ment continue to evolve, TAVR is a complex procedure
with many interlocking steps that require meticulous atten-
tion to achieve optimal results and minimize complications.
2. Team-Based Approach: A foundational requirement of
TAVR is a team-based approach to patient care.
Given the high-risk profile of patients, who often have
ortic Stenosis
Major Complications
ry or other valve surgery
ABG, aortic surgery or
e response to exercise
0.6 cm2, mean
m/s) (Class IIb, LOE: C)
● Mortality (3%)
● Stroke (2%)
● Prolonged ventilation (11%)
● Thromboembolism and bleeding
● Prosthetic dysfunction
● Perioperative complications are higher when
surgical AVR is combined with CABG
vere, symptomatic,
who have aortic and
predicted survival
surgical risk as defined
ortality or irreversible
h as frailty, prior
vere hepatic or
al AVR in patients at
: STS8%*)
● Mortality (3% to 5%)
● Stroke (6% to 7%)
● Access complications (17%)
● Pacemaker insertion
Œ 2% to 9% (Sapien)
Œ 19% to 43% (CoreValve)
● Bleeding
● Prosthetic dysfunction
● Paravalvular AR
● Acute kidney injury
● Other
Œ Coronary occlusion
Œ Valve embolization
Œ Aortic rupture
s with AS in whom
se of serious comorbid
● Mortality
● Stroke
● Access complications
● Restenosis
matic severe AS
other risk factors as
ession of AS
pes should be avoided
sk of destabilization
● Hemodynamic instability
ent is beneficial, useful, and effective; Class II: Conditions for which there is conflicting evidence
ight of evidence/opinion is in favor of usefulness/efficacy; Class IIb: Usefulness/efficacy is less
ized studies; LOE C: Only consensus opinion of experts, case studies, or standard-of-care. *The
10. During the trial enrollment phase, the minimum STS-predicted risk of mortality was changed
15.ith A
n
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plexity of the procedure involved, this team-based care
will need to include multiple contributors at different
stages in the process but will be mainly centered
around the primary cardiologist, the cardiovascular
surgeon, and the interventional cardiologist. Patients
and families must be included in the care team. Other
team members will include cardiac anesthesiologists,
heart failure specialists, structural heart disease physi-
cians, imaging specialists and the nursing care team,
among others.
. Patient Selection: In adults with severe, symptomatic,
calcific stenosis of a trileaflet aortic valve who have aortic
and vascular anatomy suitable for TAVR and a predicted
survival 12 months:
• TAVR is recommended in patients with prohibitive
surgical risk.
• TAVR is a reasonable alternative to surgical AVR in
patients at high surgical risk.
Definitions of severe AS have varied between registries,
rials, and guidelines. In general, all require severely re-
uced, calcified leaflet motion, and aortic jet velocity 4.0
/s OR an AVA 1.0 cm2 OR AV index 0.6 cm2/m2
OR a mean gradient 40 mm Hg. In the setting of LV
systolic dysfunction, severe AS is present when the leaflets
are calcified, with reduced systolic motion, and dobutamine
stress echocardiography shows an aortic velocity of 4.0
/s OR mean gradient 40 mm Hg with a valve area 1.0
m2 OR AV index 0.6 cm2/m2 at any flow rate.
Prohibitive surgical risk is defined as:
• An estimated 50% or greater risk of mortality or
irreversible morbidity at 30 days (as assessed by one
cardiologist and 2 cardiothoracic surgeons), or other
factors such as frailty, prior radiation therapy, porce-
lain aorta, and severe hepatic or pulmonary disease.
• Suitable aortic and vascular anatomy is defined as:
• Both aortic annulus size and valve plane to coronary
ostium height suitable for placement of an available
TAVR.
• Adequate vascular access for passage of the TAVR
system (femoral iliac, subclavian, axillary) or suitability
for an apical implantation approach.
TAVR is not currently recommended because of
limited available information in adults who have:
• An acceptable surgical risk for conventional surgical
AVR
• Known bicuspid aortic valve
• Failing bioprosthetic aortic valve
• Severe mitral annular calcification or severe MR
• Moderate AS
• Other (e.g., severe AR and subaortic stenosis)
In these groups, additional scientific data will need to be
collected to ascertain risk/benefit ratio prior to integration
into routine clinical care.4. TAVR Screening: Screening protocols should be part of
every TAVR evaluation. These may vary from institution
to institution. Some information may be obtained from
referring institutions, whereas some will be obtained
within the institution performing the TAVR. In the
former case, the information obtained must be of high
quality so that optimal recommendations can be formu-
lated. Requisite pieces of information include:
• Data sufficient to calculate STS score
• Measurement of clinical parameters related to the
presence of comorbid conditions such as pulmonary
function tests in patients with COPD or extent and
severity of malignancy if present
• Assessment for the degree of cognitive impairment as
appropriate
• Imaging data to confirm
X Presence and severity o f aortic stenosis
X Presence and severity of associated CAD
X Left ventricular function
X Presence and severity of associated valvular heart
disease lesions
X Presence and extent of cerebral vascular disease
• Preprocedural imaging for planning should be done
by the institution performing TAVR
X Assessment of annular size for device selection
X Assessment of details of arterial anatomy including
the peripheral aortoiliac vessels as well as the aortic
arch and ascending aorta which may impact on
access selection
5. Site Selection: Centers should have experience with struc-
tural heart disease. All members of the heart team should
be available onsite. In addition, a structural heart disease
center or clinic, a procedural performance area (either a
hybrid surgical room or a specially modified cardiac
catheterization laboratory room), a postprocedure care
team, and expert imaging using echocardiography and
CT should be available. Setting up specialized centers of
excellence with convenient access to patients should be a
top priority for responsible dissemination of this tech-
nology. For more details, please see facility requirements
in the “SCAI/AATS/ACCF/STS Multisociety Expert
Consensus Statement: Operator & Institutional Re-
quirements for Transcatheter Valve Repair and Replace-
ment; Part 1 TAVR” (218).
6. Center and Physician Experience: Expertise with surgical
AVR is essential—the number of surgical procedures has
been recommended to be 50 within the past 12 months.
For the interventional cardiologist, experience with bal-
loon aortic valvuloplasty as well as experience in a
team-based care approach is recommended. During the
rollout of the procedure, experienced proctors will form
part of the heart care team. These physicians will be
onsite for the first several cases after a site has been
initiated. After the performance of these initial proce-
dures, centers will be eligible to qualify for independent
78
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transapical, transarterial, and alternative arterial ap-
proaches for TAVR. For detailed information on re-
quirements for interventional cardiologists and surgeons
to perform TAVR, please refer to the “SCAI/AATS/
ACCF/STS Multisociety Expert Consensus Statement:
Operator & Institutional Requirements for Transcathe-
ter Valve Repair and Replacement; Part 1 TAVR.”
(218).
. Procedural Performance: TAVR should be performed in
either specially modified, large cardiac catheterization
laboratories or hybrid rooms. Fixed imaging and intrap-
rocedural echocardiography are required as are capabilities
for cardiopulmonary bypass for management of procedural
complications. In addition to the valve implantation equip-
ment, peripheral and coronary interventions equipment
must be available for urgent treatment of complications.
The ability to provide general anesthesia should be
available.
. Postprocedural Care: The intensity of postprocedural care
depends on the presence of comorbidities, as well as the
results of the TAVR itself. Protocols should be defined
for routine care, as well as management of specific
problems and complications. Ideally, a dedicated recov-
ery area should be established at each site to which all
patients should be transferred for optimal postprocedural
care. Postdischarge care plans should include consider-
ation of rehabilitation, and home health or other support
needed during recovery. In addition, follow-up with the
primary care team can ensure successful transitions of
care.
. Registries: Participation is recommended in national
TAVR registries that include clinical and administrative
claims data that will allow careful evaluation of both
short-term and long-term risks and benefits and track
changes in patient selection criteria, procedural perfor-
mance, and device iteration. Preferably, registries should
also capture demographics and mortality outcome data of
surgically and medically treated patients in order to facilitate
comparison of different therapeutic strategies to improve
identification and selection of optimal therapeutic options.
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AR  aortic regurgitation
AS  aortic stenosis
AVA  aortic valve area
AVR  aortic valve replacement
CAD  coronary artery disease
CMR  cardiac magnetic resonance
COPD  chronic obstructive pulmonary disease
CT  computed tomography
EF  ejection fraction
EOA  effective orifice area
EuroSCORE  European system for cardiac operative risk evaluation
V  left ventricular
LVOT  left ventricular outflow pact
MDCT  multidetector computed tomography
NCDR  National Cardiovascular Data Registry
PARTNER  Placement of Aortic Transcatheter Valve trial
PH  pulmonary hypertension
RV  right ventricular
SOURCE  SAPIEN Aortic Biosprosthesis European Outcome registry
STS  Society of Thoracic Surgeons
TAVR  transcatheter aortic valve replacement
TEE  transesophageal echocardiogram
TTE  transthoracic echocardiography
VARC  Valve Academic Research Consortium
